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PART I 
TARGETING NFR2 PATHWAY FOR NEUROPROTECTION AND 
REDUCTION LEVODOPA-INDUCED TOXICITY IN PARKINSON’S 
DISEASE. 
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1. INTRODUCTION 
 
1.1 PARKINSON’S DISEASE 
Parkinson's disease (PD) is a neurodegenerative disorder characterized by a 
progressive loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc). The most dramatic loss of dopaminergic neurons within the SNpc is 
typically in the ventrolateral tier, which is probably the cause of the motor 
impairment. The resultant lacking of dopamine leads to a "parkinsonism," a 
characteristic symptomatology that includes bradykinesia, muscular rigidity, rest 
tremor and postural impairment[1]. 
 
Lewy bodies are also the hallmark unique of this pathology, composed by 
insoluble and aggregated oligomers of α-synuclein within the cell body and the 
processes of neurons. This feature could also be found not only in the brain but 
including the spinal cord and peripheral nervous system[2]. 
 
 
Figure.1 Brain regions affected by Parkinson’s Disease 
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Many processes are implicated in the onset of the pathology like oxidative stress, 
mitochondrial impairments, inflammation, excitotoxicity and protein aggregates. 
The principal component of LBs inclusions is α-synuclein, which operates a major 
role in the pathogenesis of this disease. The physiological function of α-synuclein 
and the mechanism that mutations in this gene lead to neurons loss are still not 
clear, although it has been observed that an excess of α-syn depositions can 
cause dopaminergic neurons loss[3]. On the other hand, oxidative damage 
induced by reactive oxygen species (ROS) participates in the progression of 
dopaminergic neurons degeneration. In particular, the metabolism of dopamine 
(DA) might be able to raise basal levels of oxidative stress; indeed, dopamine 
oxidation leads to the formation of neurotoxic species[4].  
 
1.2 EPIDEMIOLOGY AND INCIDENCE 
PD is a progressive disease with a mean age at onset of 55, the pathology’s 
prevalence increases to 1% in persons 65 years old, this percentage reach 3% in 
individuals with age over 85 without a notable difference by the sex. In about 95% 
of cases, PD is idiopathic multifactorial disease due to environmental agents and 
genetic susceptibility; there is no apparent familiar genetic bond; these cases are 
indicated as “sporadic” PD[5]. On the other hand, residual 5% cases are the 
consequence of genetic mutations and are inherited. Normally, the pathology is 
diagnosed about 60 years of age, but in 10% of cases the onset would be earlier 
around 45 years, this is recognized by the scientific community like precocious 
incidence. 
 
The prevalence and the incidence of PD increase with age, the increase of the life 
expectancy coupled with the demographic shift in the population could explain the 
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rising number of cases seen worldwide. However, in the last two decades, it was 
observed a gradual raise in the mean age at onset of the disease and this feature 
is not entirely explained by population aging, but suggest that presumably 
additional variables may play a central role[6]. Reasonably, the increasing 
knowledge of the neurodegenerative chronic diseases, the development of the 
accuracy of diagnosis could be linked to these cases. In fact, early physical traits 
that in the past were related to aging or missed by older patients now are more 
related to the medical corps. This circumstance could also be defined by a 
reduction of cases of precocious incidence. 
 
1.3 ORIGIN AND RISK FACTORS 
Parkinson's disease is a pathology that in the 85% of the cases has a sporadic 
origin. Moreover, in about 15% of the cases, is linked to genetic causes[7]. The 
genes involved are called PARKs, which include six members. The transmission 
of these genes it is either autosomal dominant for α-synuclein, UCHL1, and 
LRRK2 or autosomal recessive transmission for parkin, DJ-1, and PINK-1. The 
recessive form is characterized by an early onset, and it usually shows the most 
severe outcome. Among the six proteins engaged in the familial forms of PD, α-
syn is clearly the most studied, not only because was the first gene identified, but 
also because is the major fibrillar protein of the Lewy bodies[8]. 
 
There are several dysfunctions noticed in PD, excitotoxicity, mitochondrial 
impairments and oxidative stress, that lead to cellular death. Oxidative stress is 
due to a disequilibrium between the levels of ROS produced and eliminated. ROS 
are produced by many pathways such as the activation of enzymes like adenine 
dinucleotide phosphate oxidase (NADPH) and nitric oxide synthase (NOS). The 
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massive production of ROS in the brain may give an explanation for the degree of 
the role that these reactive molecules operate in PD[9]. The brain utilizes about 
20% of the oxygen amount of the body, and a significant portion of that oxygen is 
transformed to ROS. Numerous evidence suggests that a major contributor to the 
dopaminergic neuronal death in PD brain are ROS, which occurs from dopamine 
metabolism, but also low glutathione (GSH) levels, and raised levels of iron and 
calcium in the SNpc. GSH is a tripeptide consisting of glutamate, cysteine, and 
glycine, with the reactive thiol group of its cysteine residue working as a powerful 
antioxidant. GSH is synthesized in the cytoplasm subsequently transported to the 
mitochondria, where it works as an antioxidant molecule. GSH, with the help of 
enzymes glutathione peroxidase (GPx) and reductase (GR), forms detoxification 
machinery against these oxidative species[10]. GSH levels are finely controlled in 
normal neurons, and alterations from the basal physiological levels can provoke 
cell death. The depletion during PD precedes mitochondrial and DA loss, and the 
degree of its damage has been seen to associate with disease severity. 
 
Another essential mechanism implicated in the pathogenesis of PD is 
excitotoxicity, a pathological process during which neurons are damaged and 
destroyed after intense stimulation of glutamatergic receptors by glutamate, the 
principal excitatory neurotransmitter in the CNS. This event is implicated in several 
pathological conditions concerning the CNS such as stroke, epilepsy and AD. 
Glutamate-mediated excitotoxicity may be involved in a vicious cycle, which 
critically gives worsening of nigrostriatal degeneration in PD[11]. 
 
Not less severe is neuroinflammation that has been seen in postmortem brain in 
the form of activated microglial pro-inflammatory cytokines in SN and striatum and 
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has been implied as part of the pathophysiology of the disease. This inflammatory 
reaction is triggered by the presence of LBs because α-syn protein is an activator 
of microglia. The importance of activation is subordinate on the amount of the α-
syn present. This can drive to the differentiation of microglia into several 
phenotypes, including antigen presenting or macrophage-like forms. The first one 
associated with lower levels of α-syn, also trigger activation of the adaptive 
immune system by CD4+ T-cells[11]. 
 
1.4 SYMPTOMATOLOGY 
PD is a disease with a slowly progressive neurodegeneration, in which motor and 
non-motor symptoms occur. The disease is recognized when one of the motor 
symptoms develop. Motor symptoms appear when at least 50% of the 
dopaminergic neurons are already lost, due to the efficient compensative 
mechanisms of the dopaminergic system.  
There are four main motor symptoms: resting tremor, bradykinesia, postural 
imbalance, and rigidity. Normally, the motor impairment appears on the dominant 
side first and gradually spread to the contralateral side, although the dominant 
side will be the most affected one. 
 
•    Bradykinesia is the symptom that disabling the most in this pathology and is 
present in 80-90% of the patients. It is characterized by slowness of the 
movements and causes inability to turn on the bed or to lift from a chair[12]. 
 
•    Rigidity is the motor impairment that causes resistance in movements, due to 
the activation of agonist and antagonist muscle at the same time. This symptom 
is shared by 90% of the patients. 
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•    Resting tremor is the most obvious manifestation of PD, and it is usually of the 
primary symptoms of the disease but on the other side the less disabling[13]. 
 
•    The postural imbalance is a late motor symptom and apparently the most 
disabling of the previous four because cause the falling and eventually injuries. 
Although treatment for this symptom works at the beginning, the resistance to the 
drugs develops fast, presumably due to the advanced stage of the disease. 
Clinical data show that there are additional non-motor symptoms that may 
introduce the motor impairments. While the traditional therapies work directly on 
the motor symptoms through the dopaminergic system, the non-motor symptoms 
need a different clinical approach[14]. The major non-motor symptoms include 
cognitive abnormalities, mood, sleep, pain and sensory disorders. The importance 
of identifying these features in advance may increase the quality of life of patients 
affected by PD. 
 
1.5 THERAPEUTIC STRATEGIES  
Parkinson disease (PD) is one of the few neurodegenerative diseases with a 
highly effective treatment for suppressing its symptoms and signs. 
In the past 50 years, levodopa (3,4dihydroxy-L-phenylalanine) has been the 
leading drug for the treatment of this disease. It provides the first opportunity for 
clinicians to understand how the parkinsonian symptoms like resting tremor, 
rigidity, postural issues, are directly linked to the dopaminergic deficiency[15]. 
The appearance of motor complications is the main problem in the long-term 
control of patients with PD, in particular, the wearing-off phenomena that may 
cause severe impairments and decrease therapy effectiveness. Approximately 
90% of patients exhibit motor impairments following 10 or more years of L-DOPA 
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therapy[16]. These adverse effects are quite related to the stage of the disease, 
dose, and duration of levodopa therapy[17]. Several trials prove that levodopa 
provides fewer side effects like hallucinations, somnolence, edema than 
dopamine agonists. However, in early Parkinson disease, dopamine agonists are 
more efficacious than levodopa also causing less dopaminergic motor 
complications, especially dyskinesia. 
Several pathogenetic issues may provide motor impairments induced by L-DOPA, 
such as the gradual degeneration of dopaminergic neurons and the diminished 
chance of L-DOPA storage. In particular, alternate dopaminergic stimulation, due 
to L-DOPA treatment, may be linked with motor complications[18]. Recent 
investigations show that oxidant formation, following L-DOPA metabolism, could 
cause dopaminergic neuronal death[19]. The limits of L-DOPA therapy are 
therefore both interactions between the drug and the neuronal circuit and intrinsic 
drug toxicity[20]. 
The modern clinical approaches to limit or to delay motor impairments include 
preventing the start of L-DOPA therapy, the use of low-dose therapy, the 
administration of drugs, which exert a constant dopaminergic stimulation and the 
reduction of dopaminergic cell loss. The current national and international 
guidelines for PD therapy propose the use of L-DOPA when the disorder 
manifestations induce functional impairments. 
Epidemiological evidence proposes that dietary antioxidants, like vitamins and 
polyphenols, may work as disease-modifying neuroprotective compounds, by 
modulation the neuronal death in both in-vitro and in vivo models[21]. Other 
dietary compounds, besides the well-known antioxidants, may represent 
treatment avenues for chronic neurodegeneration. 
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Sulforaphane 4-(methylsulfonyl)butyl isothiocyanate, SFN is a glucosinolates 
derived isothiocyanate found in cruciferous vegetables. Isothiocyanates are 
obtained from vegetables such as broccoli, cauliflower and Brussel sprouts and 
their detoxicant, and anticancer activity has been reported[22]. 
Recent studies have confirmed possible neuroprotective results of SFN in several 
neurodegenerative models. Indeed, SFN and its glucosinolate using decrease 
inflammation and ischemia in the CNS, this effect explains that SFN is able to 
cross the blood brain barrier (BBB) and prevent post-traumatic cerebral 
edema[23]. As with other isothiocyanates, SFN’s neuroprotective mechanisms of 
action is not yet known. 
 Novel in vitro findings have revealed that continued SFN treatment protects 
neurons upon H2O2 damage and against 6-hydroxydopamine but it does not 
confer any outcome against another neurotoxin used as a PD model, 1 methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). SFN may exert its effect by modulating 
the gene expression of phase II enzymes, which are recognized for their 
antioxidant and detoxicant action[24]. These results highlight that SFN limits the 
beginning phase of the neurodegenerative process, and neuroprotective results 
of SFN could be ascribed to the improvement of cellular antioxidant protection. 
The ability of SFN to directly prevent and to rescue neuronal damage has not yet 
been established. 
Despite antioxidants and supplements could apparently assist in the treatment of 
PD, clinical investigations have confirmed that tocopherol, coenzyme Q10, and 
glutathione seem to have a poor role in the prevention or treatment of PD[25]. One 
of the purposes for this failure is presumably the small “therapeutic window” of 
direct antioxidants in patients with neurodegenerative diseases. In fact, oxidative 
impairment is usually substantial, and the degenerative process has already 
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begun at the time of the diagnosis. Consequently, antioxidants have a limited role 
in the area of neuroprotection and in particular in PD therapy. Hence, the 
difficulties of the neurodegenerative process and their complexities induced by 
long-term L-DOPA therapy have not yet been resolved. 
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2. METHODS 
 
2.1 CELL CULTURES 
Human neuronal-like SH-SY5Y were acquired from ATCC (USA). The cells were 
grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine 
serum (FBS), 2mM glutamine, 50 U/ml penicillin and 50ug/ml streptomycin. The 
cells were kept at 37°C in a humified incubator with 5% CO2. 
 
2.2 L-DOPA 
3,4-Dihydroxy-L-phenylalanine (L-DOPA) was purchased by Sigma-Aldrich. L-
DOPA was freshly prepared every use. The powder was dissolved in distilled and 
filtered water to obtain a stock solution. The working solution was diluted directly 
in the culture media. 
 
2.3 SULFORAPHANE 
The Sulforaphane (SFN) was acquired from LDK (USA). The powder was 
dissolved in dimethylsulfoxide (DMSO) to obtain 10uM stocks. The aliquots were 
stored at -20°C. 
2.4 DETERMINATION OF CELLS PROLIFERATION 
The MTT [3-(4,5- dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] 
assay was used to assess the in vitro cytotoxicity of L-DOPA and SFN used in 
this study. SH-SY5Y cells (100 μl; 1x105 cells/ml) were seeded into 96 well 
plates and left to adhere for 24h. The next day, the medium was removed from 
the wells and replaced with a medium containing L-DOPA and SFN for 24h at 
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37°C in 5% CO2. After the treatment, the cells were washed with phosphate 
buffered saline (PBS) and then incubated with MTT (5 mg/ml) in PBS for 4h. 
After removal of MTT and additional washing, the formazan crystals were 
dissolved in isopropanol. The amount of formazan was measured (405 nm) with 
a multilabel plate reader (VICTORTM X, Perkin Elmer Inc., MA, USA). 
2.5 APOPTOSIS ASSAY 
Dual staining with fluorescent Annexin-V/propidium iodide (PI) double-staining 
system (Roche diagnostic GmbH, Mannaheim, Germany) has been used to 
discriminate apoptotic and necrotic cell death, in which Annexin V-positive/PI-
negative staining is regarded as apoptosis and PI-positive staining as necrosis. 
During apoptosis, a loss of phospholipid asymmetry leads to exposure of 
phosphatidylserine (PS) residues on the outer leaflet of the plasma membrane. 
Exposed PS residues bind the annexin V in the presence of calcium. Necrotic 
cells, expose PS residues but losing membrane function allow the propidium 
iodide (PI) to enter into the cell and bind the DNA as shown in Fig.1 
 
 
Fig.1 Representation of the labeling mechanism of cells in the presence of the Annexin-
V/propidium iodide 
 
In order to evaluate the neuroprotective effects of SFN against L-DOPA-induced 
neurotoxicity, an experimental approach using SH-SY5Y cells, a dopaminergic 
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neuronal cell line, was applied. A pulse/chase treatment has been used, which 
means a short exposure of neurons to L-DOPA and then it is removed to allow the 
activation of neuronal cell death mechanisms. In particular, apoptotic events and 
necrosis are detected after 15h of 3h treatment with L-DOPA, at the end of the 
treatment the cells were incubated with 100uL of the labeling solution at 25°C 
covered with aluminum foil for 15min. To evaluate the percentage of labeled cells, 
five random areas with about 100 cells were examined under a fluorescence 
microscope (Zeiss Axio Imager M1, Oberkochen, Germany). The percentage of 
apoptotic cells was calculated by the formula: (Annexin-V-positive cells/ n° total 
cells) x 100. 
 
2.6 DETERMINATION OF INTRACELLULAR GLUTATHIONE 
LEVELS 
The evaluation of the intracellular glutathione level was quantified through a 
monoclorobimane dye (MCB, Fluorescent Dyes, Los Angeles, USA). The SH-
SY5Y were co-treated for 24h with a combination of L-DOPA 25uM and 
sulforaphane 0,63uM. At the end of the treatment, the media was removed from 
the wells, and the MCB 10uM was incubated with the cells for 30 mins at room 
temperature in the dark. The GSH levels were quantified by using a 
spectrofluorometer (TECAN Genios, Switzerland). The results were displayed as 
a fold increase versus the control. 
 
Fig.2 representation of the chemical reaction between the MCB and GSH 
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2.7 ELISA ASSAY FOR ACTIVATED NRF2 TRANSCRIPTION 
FACTOR 
The evaluation of the nuclear Nrf2 levels was collected by using TransAM® Nrf2 
Transcription Factor ELISA Kit (Active Motif, Belgium). The Kit is composed of a 
96 wells plate in which oligonucleotides containing ARE sequences (Nrf2 binding 
sites) are immobilized at the bottom of the wells. Active Nrf2 contained in the 
nuclear extracts binds the ARE sequences. A specific antibody directed against 
Nrf2 plus a secondary antibody conjugated to horseradish peroxidase (HRP) 
provides a colorimetric reaction that could be easily detected by a 
spectrophotometer. 
 
 
Fig.3 Representation of the main steps of the NRF2 ELISA assay 
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2.8 QUANTITATIVE REAL-TIME PCR 
RNA was extracted from SH-SY5Y cells using the RNeasy mini kit (Qiagen) and 
following manufacture’s procedures. cDNA was synthesized using the High 
capacity RNA-to-cDNA Kit (Applied Biosystem). qRT-PCR was carried out using 
Taqman Universal Master Mix II (Applied Biosystem) and the average mRNA fold 
change of each target gene was calculated by comparing the CT (cycle threshold) 
of the target gene to that of the housekeeping gene 18-S. All reactions had three 
technical replicates and each condition had three biological replicates. The 
Taqman probes span an exon junction. 
Relative quantification was with the ΔΔCT method (2(−ΔΔCT)), and P values were 
calculated by t-test. The wild type was used as the calibrator to assess fold change 
in gene expression.  
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3. RESULTS 
 
3.1 NEUROTOXIC EFFECTS OF L-DOPA  
First, we evaluated the neurotoxic profile of L-DOPA in the SH-SY5Y human 
neuroblastoma cell line. SH-SY5Y cells were treated for 24 h with various 
concentrations L-DOPA (25-100 µM). Treatment with 50 and 100 µM of L-DOPA 
led to a significant increase of neurotoxicity (Fig.1). 
 
 
Figure 1. Neurotoxic effects of L-DOPA in SH-SY5Y cells.  SH-SY5Y cells were 
treated for 24 h with various concentrations L-DOPA (25-100 µM). At the end of 
treatment, cell viability was measured using MTT assay as described in the 
materials and methods section. The values are expressed as a percentage of 
cell viability decrease respect to untreated cells. The data shown as mean ± 
SEM (n=4-5). §§p<0.01 vs control; at ANOVA with Dunnet post hoc test. 
 
 
3.2 SULFORAPHANE COUNTERACT THE NEUROTOXICITY 
INDUCED BY L-DOPA 
Several studies show that L-DOPA-induced neurotoxicity it may be caused by an 
increase of ROS, probably due to its autoxidation and metabolism. Among 
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indirect antioxidant molecules, isothiocyanates, derived from the glucosinolate 
hydrolysis found in cruciferous vegetables, have recently gained attention as 
potential neuroprotective compounds that induce antioxidant phase 2 enzymes 
and molecules through transcription factor Nrf2-dependent antioxidant response 
element activation. However, the potential neuroprotective effects of SFN 
against the neurotoxicity elicited by L-DOPA still remain unanswered. Therefore, 
a co-treatment with L-DOPA 100 µM and SFN 0.63-2.5 µM was applied on the 
SH-SY5Y. As showed in Fig.2, SFN counteracted the L-DOPA-induced 
neurotoxicity, showing a significant dose-response inhibition of the neurotoxicity 
with the maximum effect at 2.5 µM. 
 
Figure 2. SFN counteracts the neurotoxicity induced by L-DOPA in SH-SY5Y 
cells. SH-SY5Y cells were treated with various concentrations of SFN (0.63-2.5 
μM) and L-DOPA (100 μM) for 24 h at 37°C. At the end of treatment, cell viability 
was measured using MTT assay as described in the materials and methods 
section. The values are expressed as a percentage of cell viability decrease 
respect to untreated cells. The data shown as mean ± SEM (n=4-5). §§§p<0.001 
vs control, *p<0.05 and **p<0.01 vs cells treated with L-DOPA; at ANOVA with 
Dunnet post hoc test. 
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3.3 SULFURAPHANE PREVENTS THE NEUROTOXICITY 
INDUCED BY L-DOPA 
Neurohormesis is the adaptive response of the organism to stress including 
environmental “toxins”. Many phytochemicals frequently function as toxins that 
defend the plants against insects and other damaging organisms. However, at 
the relatively low doses consumed by humans and other mammals these same 
“toxic” phytochemicals begin pathways that can shield the cells against a type of 
adverse circumstances. We evaluated the ability of the SFN to induce a 
neurohormetic response against a subsequent L-DOPA-induced toxicity. SH-
SY5Y cells were treated with various concentrations of SFN 0.63-2.5 μM for 24 h 
and then treated with L-DOPA 100 μM. SFN showed a significant ability to 
prevent the cell death induced by L-DOPA with a neuroprotection more efficient 
than the co-treatment L-DOPA and SFN (Fig.3) 
 
Figure 3. SFN prevents the neurotoxicity induced by L-DOPA in SH-SY5Y cells. 
SH-SY5Y cells were treated with various concentrations of SFN (0.63-2.5 μM) 
for 24 h and then treated with L-DOPA (100 μM) for 24 h at 37°C. At the end of 
treatment, cell viability was measured using MTT assay as described in the 
materials and methods section. The values are expressed as a percentage of 
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cell viability decrease respect to untreated cells. The data shown as mean ± 
SEM (n=4-5). §§§p<0.001 vs control, **p<0.01 and ***p<0.001 vs cells treated 
with L-DOPA; at ANOVA with Dunnet post hoc test. 
 
3.4 THE COMBINATION OF SFN AND L-DOPA PREVENTS THE 
APOPTOSIS INDUCED BY H2O2  
To investigate the potential therapeutic strategy based on a neurohormetic 
effect, a pre-treatment with L-DOPA and SFN with low and not toxic 
concentration was applied. SH-SY5Y cells were treated for 24 h with 
concentrations of L-DOPA (25 μM) and SFN (0.63 μM) not associated with 
neurotoxic and neuroprotective effects. The pre-treatment allowed the cells to 
activate the adaptive cellular stress response and counteract the subsequent 
oxidative stress elicited by 300 μM of H2O2 (Fig. 4). In particular, we recorded a 
significant synergic effect in the combination L-DOPA and SFN with a strong 
reduction of the apoptosis compared with the single pre-treatments. 
 
Figure 4. The combination of SFN and L-DOPA prevents the apoptosis induced 
by H2O2 in SH-SY5Y cells. SH-SY5Y cells were treated with SFN (0.63 μM) and 
L-DOPA (25 μM) for 24 h and then treated with H2O2 (300 µM) for 2 h at 37°C. 
After a further 16 h of treatment with medium without H2O2, neuronal apoptosis, 
in terms of membrane phosphatidylserine exposure (Annexin V binding) was 
determined as described in the materials and methods section. The values are 
expressed as a percentage of Annexin V labeled neurons respect to untreated 
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cells. The data shown as mean ± SEM (n=3-4). §§§p < 0.001 vs control, ***p < 
0.001 vs. cells treated with L-DOPA; at ANOVA with Bonferroni post hoc test. 
 
3.5 SFN POTENTIATES THE INCREASE OF NRF2 mRNA AND 
NRF2-ARE BINDING ACTIVITY INDUCED BY L-DOPA. 
The transcription factor Nrf2 is a basic leucine zipper (bZIP) protein that 
regulates the expression of antioxidant proteins that protect against oxidative 
damage. We wanted to address our findings testing the role of Nrf2 in the 
neuroprotection afforded by the treatments with L-DOPA 25 μM and SFN 0.63 
μM. A kinetic treatment with different conditions was applied, and the Nrf2 
mRNA level was quantified. We observed that after 3h of treatment L-DOPA was 
able to double the amount of mRNA of Nrf2 and that this increase is potentiated 
by SFN (Fig.5a). Nrf2 exerts function when is activated, migrating from the 
cytoplasm to the nucleus and binding ARE sequences. To evaluate the amount 
of Nrf2 activated, an ELISA assay was performed. Interestingly, the co-treatment 
L-DOPA and SFN for 2h is the only condition in which we recorded a peak of 
Nrf2 activated (Fig.5b). 
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Figure 5. SFN potentiates the increase of Nrf2 mRNA (a) and Nrf2–ARE binding 
activity (b) induced by L-DOPA. SH-SY5Y cells were treated for different times 
with the combination of SFN (0.63 µM) and L-DOPA (25 µM) in the absence of 
treatment with H2O2. After 1-6 h of treatment, Nrf2 mRNA and Nrf2–ARE binding 
activity levels were measured as described in the materials and methods 
section. The values are expressed as fold increase respect to untreated cells. 
The values are shown as mean ± SEM (n=3-4). **p<0.01 and ***p<0.001 vs cells 
treated with L-DOPA for the same treatment time; §§p<0.01 and §§§p<0.001 vs 
cells treated with L-DOPA 1h at ANOVA with Bonferroni post hoc test. 
 
3.6 SFN POTENTIATES THE INCREASE OF GSH INDUCED BY L-
DOPA 
The activation of Nrf2 results in the induction of many cytoprotective proteins. 
We wanted to test the level of glutathione (GSH), one of the most important 
downstream target of Nrf2. GSH is capable of preventing damage to important 
cellular components caused by reactive oxygen species such as free radicals, 
peroxides, lipid peroxides, and heavy metals. We treated the SH-SY5Y for 24h 
with L-DOPA and SFN. As shown in Fig.6, L-DOPA increase the level of GSH 
and the co-treatment L-DOPA and SFN potentiates the response. 
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Figure 6. SFN potentiates the increase of GSH induced by L-DOPA.SH-SY5Y 
cells were treated for different times with the combination of SFN (0.63 µM) and 
L-DOPA (25 µM) in the absence of treatment with H2O2. After 24 h of treatment, 
GSH levels were measured using MCB as described in the materials and 
methods section. The values are expressed as fold increase respect to 
untreated cells. The values are shown as mean ± SEM (n=3-4). §p<0.05 vs 
control and *p<0.05 vs cells treated with L-DOPA; at ANOVA with Bonferroni 
post hoc test. 
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4. DISCUSSION 
 
L-DOPA is the most prescribed drug for controlling the symptoms of Parkinson's 
disease. However, a prolonged use of L-DOPA causes side effects like dyskinesia 
and gradual reduction of efficacy with the time. In order to potentiate the current 
treatment through the association of L-DOPA with other molecules, it is necessary 
to identify the cytotoxic mechanism of this drug. Neuronal death through apoptosis 
is hard to identify in vivo because apoptotic cells are immediately phagocytosed 
without generating any damage to the surrounding tissue. Because of the lacking 
of proof of its toxicity, it is difficult to prove that a long-term administration of L-
DOPA may intensify neuronal damage and accelerate the Parkinson's 
progression. It has been proven that L-DOPA causes a neuronal death in vitro 
through apoptotic pathways mediated by an increase of ROS. Indeed, researchers 
found that L-DOPA toxicity was reduced in the presence of antioxidants 
(Walkinshaw 2016). Oxidative stress occurs when there is an impairment of the 
equilibrium between pro-oxidant molecules and antioxidant levels, and has been 
linked to the pathogenesis of several neurodegenerative diseases, ischemia, 
cancer, etc. 
Discovering the mechanism of cell death produced by L-DOPA has significant 
implications for the treatment of Parkinson's disease. 
 
This study was aimed to evaluate the antioxidant activity of SFN against L-DOPA 
and H2O2 toxicity to identify new therapeutic strategies for reducing side effects of 
the L-DOPA therapy. We initially identified a toxic concentration of L-DOPA 
(100µM) able to induce about 50% of neuronal death and found that SFN was 
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able to promote a significant decrease of L-DOPA-induced neurotoxicity dosage-
dependent (0.63-2.5µM) suggesting that SFN counteracts the oxidative 
metabolites generate from L-DOPA. We found that co-treatment with a low dosage 
of L-DOPA (25µM) and SFN (0.63µM) not able to cause toxicity individually in 
neurons, can protect the cells from a subsequent oxidative stress induced by 
H2O2, reducing the neuronal death at the same levels of the sham. This 
phenomenon could be ascribed as “neurohormesis” in which some molecules at 
subtoxic doses activate adaptive cellular stress-response pathways in neurons.  
We underlined that this mechanism involves the activation of the transcription 
factor NRF2, known to induce antioxidant response through the activation of the 
transcription of several genes cytoprotective and detoxifying such as CYP1A1, 
GST, and NQO1.  
 
In our work, we observed a transcriptional increase of NRF2 after 3h of treatment 
with the combination L-DOPA (25µM) and SFN (0.63µM) that suggests the 
involvement of NRF2 in the neuroprotection observed. Furthermore, we found that 
there is a peak after 2h of treatment of the nuclear concentration of NRF2. NRF2 
in physiologic conditions is localized in the cytoplasm inhibited by its repressor 
Kelch like-ECH-associated protein 1 (KEAP1). Its migration to the nucleus that 
drives the transcription of protective genes occur under stress conditions. We 
hypothesize that the 2h peak of NRF2 causes an imbalance between the 
cytoplasmic and nuclear NRF2 that drives the increase of its transcription after 3h 
of treatment.  
ROS in the brain tissue is counteracted by the increase in antioxidant molecules 
like glutathione (GSH). GSH is the main player in the detoxification against 
oxidative species, and its regulation is controlled by NRF2 by the regulation of 
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glutathione S-transferase (GST). Our findings show that SFN (0.63µM) 
potentiates the increase of GSH observed with L-DOPA (25µM) treatment, 
justifying the increase of NRF2 observed.  
 
Taken together, these results demonstrate that SFN protects dopaminergic 
neurons against oxidative injury induced by high doses of L-DOPA also blocking 
the progression of the damage. Therefore, SFN's neuroprotective effects could 
not be ascribed to the induction of the synthesis of antioxidant molecules and 
enzymes, but they could be due to the ability of SFN to interact with specific targets 
of L-DOPA damage. Synergic neuroprotective effects are also very interesting, 
especially for the low concentrations, highlighting a high specificity in the 
mechanisms of action. 
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PART II 
KNOCK-OUT OF A MITOCHONDRIAL SIRTUIN PROTECTS 
NEURONS FROM DEGENERATION IN C. elegans 
 
 
 
 
 
 
 
 
 
 
 
 30 
1. INTRODUCTION 
1.1 STROKE 
 A continuous supply of blood to the brain is essential for maintaining function and 
integrity.  A disturbance of the blood flow can lead to stroke, in which a clot or the 
bursting of a blood vessel interrupts the transport of nutrients and oxygen to the 
brain tissue. Ischemia, caused by a clot, accounts for about 85% of all strokes, 
while hemorrhagic stroke accounts for about 15% [26].  
 
Stroke is one of the leading causes of mortality in the United States and one of 
the leading causes of adult disability, with more than 4 million stroke survivors in 
the United States alone [27]. Approximately 90% of stroke survivors are left with 
some residual deficit, among which 30% require continued assistance and 70% 
are unable to resume work [28]. Gender seems to be important both in the 
prevalence and outcome of stroke. Not only have women been shown to have a 
higher risk of developing stroke, but the outcome is generally poorer than that 
observed in men, especially with progression of age [29]. 
 
Fig.1 Ischemic and hemorrhagic strokes.  
 
Stroke leads to massive neuronal death, in which the damage is proportional to 
the severity, duration, and localization of the stroke. Moreover, neuronal death 
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occurs differently in different brain regions depending on their distance from the 
blocked or burst blood vessel. Severe ischemia occurs in the central zone, 
referred to as the core, causing irreversible neuronal death [30]. Just outside the 
core, another area of the brain tissue, called penumbra is also damaged, but to a 
lesser extent. In the penumbra, the damage of stroke is potentially reversible [31]. 
For this reason, the penumbra is the main target for therapeutic intervention [30]. 
 
While stroke is a major area of medical research, effective strategies to protect 
against the permanent damage of neuronal death due to stroke are still not 
available. There are several new drugs in trial stages for the treatment of stroke. 
However, the plasminogen activator (tPA), which has been shown to improve 
outcomes in both sexes, is the only FDA-approved drug currently available [32] 
 
   
Fig.2 Stroke events. Meheta and Vemuganti, journal.aavs, 2014 
 
1.2 MOLECULAR MECHANISMS OF CELL DEATH IN STROKE 
The major excitatory neurotransmitter in the mammalian central nervous system 
(CNS) is glutamate [33]. Glutamate binds both ionotropic and metabotropic 
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receptors. In a physiologic condition, the activation of these receptors is well 
regulated. During an ischemic stroke, the level of glutamate raises to a 
concentration toxic to neurons [34]. 
The excessive calcium influx through the activation of glutamate receptors and 
from endoplasmic reticulum causes a dysregulation of the regulatory mechanism 
and leads to the activation of lipases, phosphatases, endonucleases, and calcium-
dependent proteases that immediately destroy the cell and mitochondria integrity 
[35].  
 
Glutamate receptors are also responsible for an excessive increase of sodium, 
which causes an influx of water, leading to cell swelling and edema [36]. Moreover, 
the increase of Na+, Ca2+, and ADP in ischemic cells ultimately leads to an 
overstimulation of the mitochondrial production of reactive oxygen species, or 
ROS [37]. ROS directly damage lipids, proteins, carbohydrates, and nucleic acids. 
Inflammation also plays a crucial role in the pathogenesis of the ischemic stroke 
[38]. Cytokines, such as IL-1, IL-6, TNF-alpha, and TGF-beta, and adhesion 
molecules, such as selectins, integrins, and immunoglobulins, are involved in the 
inflammatory response, the beginning of which contributes to irreversible brain 
damage. In addition, ROS can increase inflammation directly by increasing blood 
brain barrier (BBB) permeability via the up-regulation of vascular endothelial 
growth factor (VEGF) and induction of the expression of cytokines and NF-kb. 
These events and reperfusion result in several types of neuronal death including, 
autophagy, necrosis, and apoptosis [39]. 
The periinfarct area surrounding an acute ischemic event is characterized by 
apoptosis, which has been linked to an enhanced expression of p53 [40]. p53 
migrates to the mitochondria where it binds and inactivates Bcl-XL, causing cyt C 
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release and activation of caspase-9 [41]. Caspase-9 begins the activation of other 
caspases, of which caspase-6 appears to be involved in axonal degeneration. 
Moreover, several studies suggest the involvement of autophagy after ischemic 
events. The hypoxia-inducible factor (HIF) seems to be a key regulator of 
autophagy through the activation of autophagic genes [42]. 
 
1.3 DEG/ENaC CHANNELS TOXICITY 
DEG/ENaCs channels are expressed in many organisms extending from the 
nematode Caenorhabditis elegans to mammas (ASICs). They are involved in 
sensory perception, such as touch sensation [43], thermosensation [44], 
proprioception [45] vascular and visceral mechanotransduction [46] and pain 
sensation [47]. DEG/ENaC channels share common characteristics and domains. 
They are 550-950 amino acid long transmembrane proteins, with two 
transmembrane helices (MSDI and MSDII), small intracellular N- and C- termini, 
and a significant extracellular cysteine-rich domain [48].  
 
In C. elegans, the most studied DEG/ENaC is the MEC touch-transducing channel 
complex, which combines subunits MEC-4 and MEC10, stomatin-related MEC-2, 
and paraoxonase-related MEC-6 [49]; [50]. MEC-4 and MEC-10 share 48% 
identity, related to subunits of the ENaC channels in mammals [51]. MEC-4 is 
expressed only in the six touch neurons, while MEC-10 is also expressed in four 
other neurons (FLPs and PVDs) in which it mediates harsh touch and/or stretch 
sensitive response behaviors. DEG/ENaC channels can be hyperactivated either 
by a genetic modification, indicated by ‘d’, or by acidification of the extracellular 
environment [52].  
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Fig.3: The six touch sensing neurons in C. elegans labeled with a GFP tag. 
 
The hyperactivation of MEC-4(d) triggers neuronal necrosis through an increase 
of intracellular Ca2+ release from the ER and activation of calpain and cathepsin 
proteins. 
 
Fig.4: Neuronal death is mediated by hyperactivation of MEC-4 channel (Goodman et al., 
2002). 
 
The block of DEG/ENaC by a pharmacological approach using amiloride or by 
genetic mutations has been shown to protect neurons from death. In fact, point 
mutations that inhibit ion flux through the channel can prevent neuronal death, 
suggesting that the cation flux is essential for the neuronal death induced by 
hyperactivation of the DEG/ENaC channels. 
 
Ca2+ permeability seems to be essential for the hyperactivation of these channels. 
Indeed, Bianchi et al. demonstrated that MEC-4(d) is Ca2+ permeable. Another 
example is the mammalian ASIC1a that results Ca2+ permeable under ischemic 
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conditions [53]. During the hyperactivation of the DEG/ENaC channels, Ca2+ 
overload that causes neuronal death is thought to derive from the extracellular 
compartment and the endoplasmatic reticulum [54]. 
 
Hyperactivation of the DEG/ENaC channels causes neuronal swelling and death 
that shows all the hallmarks of necrosis. The homeostatic mechanism that 
prevents cells from swelling is mediated by the Na+-K+ ATPase, which pumps Na+ 
outside of the cell. During and ischemic event, the oxygen and ATP deprivation 
leads to the block of the sodium-potassium pump, which in turn causes 
accumulation of Na+ in the cells and the subsequent entry of water, leading to cell 
swelling. The following depolarization leads to enhanced excitability and release 
of neurotransmitters. Excessive glutamate release induces direct calcium entry 
via hyperactivated postsynaptic calcium permeable ionotropic receptors NMDA or 
indirectly by AMPA and kainite receptors, which activate voltage-gated calcium 
channels or cause sodium/calcium exchanger to operate in reverse. Calcium 
overload induces downstream activation of calcium-dependent enzymes that 
dismantle the cell.  
 
1.4 CHEMICAL ISCHEMIA 
Chemical ischemia can be used experimentally to simulate in vitro certain aspect 
of ischemic brain injury. In this model, Na+ azide or Na+ cyanide, inhibitors of 
oxidative metabolism, usually together with 2-deoxyglucose, an inhibitor of 
glycolysis, are utilized to induce hypoxia and hypoglycemia in cultures [55], brain 
slices [56], and in vivo [57]. 
These drugs block the functioning of the electron transport chain by the inhibition 
of the Hem groups of cytochromes in cytochrome oxidase (Complex IV). As a 
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consequence, redox reactions in the respiratory chain will arrest, energy will not 
be released, proton pumps will not work, protons will not pass through Complex 
V, and the production of ATP will stop. 
Chemical ischemia has also been used in C. elegans [58]. C. elegans neurons, 
myocytes, and the whole animal are injured and killed by hypoxic exposure [58]. 
HIF-1 plays a central role in mammalian oxygen homeostasis and its induction 
has been documented under chemical ischemia condition, supporting that this 
model is a simple and reliable for the study of physical hypoxia. 
 
1.5 SIRTUINS 
1.5.1 MAMMALIAN SIRTUINS 
Sirtuins are a group of proteins initially described as NAD+- dependent 
deacetylases [59]. The acylation of lysine is one important form of post-
translational modification (PTM), comprising the addition of an acyl group to a 
lysine residue in proteins. This reversible modification changes the charge of the 
lysine residue, causing an alteration of the enzyme activity, structure, and 
substrate specificity of the target [60]. Because of their ability to deacetylate a wide 
class of protein targets, sirtuins are linked to the regulation of various cellular 
processes, with well-described functions in metabolism, gene transcription, 
differentiation, apoptosis, antioxidant resistance, and lifespan[61]. 
For these reasons, it is easy to understand their involvement in a large number of 
human diseases including neurodegenerative diseases, cancer, and metabolic 
diseases. 
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Sirtuins are phylogenetically conserved, from bacteria to mammals. Sir2 was the 
first sirtuin to be identified in yeast almost ten years ago, where mutants showed 
lifespan extension by suppressing genome instability [62, 63]. Since then, the 
interest of sirtuins in longevity and health-promoting effects has increased. There 
are seven sirtuins in mammals (SIRT1-SIRT7), all sharing a common catalytic 
domain and NAD+-binding site [64].  
The deacetylase activity is exerted on different targets, such as histones, apoptotic 
modulators, and transcription factors [65, 66]. The fact that they depend on NAD+ 
instead of Zn2+ like other deacetylases, supports their dependence on the energy 
state of the cell. SIRT1 is the evolutionary closest member to Sir2 and, for this 
reason, has been the most studied of the seven sirtuins. 
 
 
Fig.5 Human sirtuins and their functions 
  
In addition, it has been recently shown that sirtuins catalyze other types of 
enzymatic reactions Fig.5, suggesting that additional sirtuins functions may still be 
awaiting discovery. 
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1.5.2 THE NUCLEAR SIRTUINS SIRT1, SIRT6, SIRT7 
SIRT1 
SIRT1 removes acetyl groups from lysines using NAD+ as cofactor, forming 
deacetylated protein, 2-O-acetyl-ADP-ribose, and nicotinamide as a 
consequence. SIRT1 deacetylates and reduces the activity of central regulator 
proteins like p53, FOXO1, and FOXO4 [67]. Under oxidative stress, SIRT1 
enhances the cell protection to stress and decreases the apoptotic capacity of 
FOXO3.  Indeed, overexpression of SIRT1 in mice induces lifespan extension and 
the appearance of phenotypes correlated with delayed aging, such as 
improvement in terms of elevated physical activity, decrease of body temperature, 
oxygen consumption, and quality of sleep[68]. Conversely, repression of SIRT1 in 
mice abolishes the result of lifespan extension[69]. 
Moreover, sirtuin inhibitors, such as sirtinol, can be beneficial as therapeutic 
agents since up-regulated SIRT1 has been reported in cancer cell lines[70], 
suggesting the possibility that SIRT1 inhibition might suppress cancer cell 
proliferation. In addition to cancer treatment, sirtuin inhibitors have also been 
suggested in the treatment of Parkinson’s disease[71], leishmaniosis[72], and 
human immunodeficiency virus[73], among others. Furthermore, increase dosage 
of SIRT1 C. elegans homolog sir-2.1 extends nematode lifespan by 50% [74] and 
knock-out of sir-2.1 abolishes life-extension mediated by caloric restriction [75].  
Recent findings demonstrated that SIRT1 increases mitochondrial biogenesis by 
deacetylation of target proteins, such as peroxisome proliferator activated 
receptor co-activator1α (PGC-1α), a primary modulator of the gluconogenic 
pathway[76], and hypoxia-inducible factor 1α (HIF-1α)[77]. Overexpression of 
SIRT1 in liver can enhance expression of PPARα and activate PGC-1α, which has 
effects on oxidative metabolism and regulates lipid metabolism in response to 
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nutrients and hormonal signals.  In addition, HIF-1α and HIF-2α bind directly to 
HIF-responsive elements (HREs) on the SIRT1 promoter, boosting expression of 
SIRT1. These studies proposed potential therapeutic advantages of SIRT1 
activation for metabolic and other aging-related disorders. 
 
SIRT6 AND SIRT7 
SIRT6 and SIRT7 are nuclear proteins with a different subnuclear localization 
compared to SIRT1. SIRT6 is associated to heterochromatic regions, while SIRT7 
is in nucleoli. 
SIRT6 was reported as a mono ADP-ribosyltransferase, acting on H3K9ac and 
H3K56ac, preserving telomere integrity and genome stability[78]. SIRT6 knockout 
mice exhibit enhanced cellular sensitivity to genotoxic stress with errors in base 
excision repair (BER), short lifespan, and aging-like phenotypes[79]. SIRT7, on 
the other hand, seems to control tissue homeostasis by deacetylation of p53 and 
regulation of rDNA transcription[80]. Due to the similar role of SIRT1 and SIRT7 
in activating p53, these two sirtuins may act together, however, this theory has not 
yet been proven. 
 
1.5.3 THE CYTOPLASMIC SIRTUIN SIRT2 
SIRT2 is mainly localized in the cytoplasm, but migrates to the nucleus during G2 
to M transition. Many studies suggest that SIRT2 functions in regulating cell cycle 
progression. Overexpression of SIRT2 blocks cell cycle in starfish oocytes and 
SIRT2 expression is downregulated in several cancers including melanomas, 
gastric carcinomas, and gliomas[81]. SIRT2 mediated deacetylation of alpha-
tubulin and H4K16ac before mitosis might also mediate cell cycle control. Impaired 
microtubule stability and altered cytoskeleton structure mediated by SIRT2-
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mediated tubulin deacetylation has been linked to neuronal degeneration and 
interferes with oligodendrocyte differentiation[82]. SIRT2 seems to be upregulated 
in white adipose tissue under caloric restriction (CR) and represses adipocyte 
differentiation by deacetylating FOXO1. These findings propose a crucial role of 
this sirtuin as an energy sensor and chief regulator of metabolic pathways in 
response to nutrient deprivation. 
 
1.5.4 THE MITOCHONDRIAL SIRTUINS SIRT3, SIRT4, SIRT5  
SIRT3, SIRT4, SIRT5 are found in the mitochondria and play a significant role in 
the regulation of the PTMs in this organelle. SIRT3 is localized in the mitochondrial 
matrix and is the best-described mitochondrial sirtuin. One of SIRT3 targets is the 
Acetyl-CoA 2 (AceCS2), a key mitochondrial enzyme implicated in several 
pathways, including cholesterol and fatty acid synthesis[83]. 
 
SIRT4 was initially described to have NAD+-dependent ADP-ribosylation activity. 
Hagis et al. found the mitochondrial enzyme GDH to be a target of SIRT4. SIRT4, 
which is highly expressed in the beta cells of the pancreas, downregulates the 
activity of GDH, reducing mitochondrial ATP production and impairing insulin 
secretion[84]. While initial investigations focused on insulin secretion, later studies 
proposed other roles for SIRT4. The knockout of SIRT4 in mouse hepatocytes 
and myotubes increases the expression of fatty acid and mitochondrial 
metabolism genes[85]. SIRT4 was found to deacetylate malonyl-CoA 
decarboxylase (MCD), an enzyme that generates acetyl-CoA from malonyl-CoA.  
In addition to interfering with lipid catabolism, deficiency of SIRT4 has been shown 
to improve resistance to induction of the mPTP, influence mitochondrial 
uncoupling through the adenine nucleotide translocator2 (ANT2), and stimulate 
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enhanced entry of glutamine-derived carbon into the TCA cycle by raising GDH 
activity[84]. SIRT4 has also been reported to be involved in backward signaling 
from the mitochondria to the nucleus into an axis involving AMPK and PGC1α. 
Recent studies identified new target proteins, including mitochondrial heat shock 
protein 60 and Stress-70, associated with cell proliferation and aging. Other 
publications recognized a novel role for SIRT4 as a lipoamidase enzyme. It was 
found that SIRT4 mediates the lipoamidation of pyruvate dehydrogenase (PDH) 
that leads to an inhibition of PDH activity that is an important link between 
glycolysis and TCA cycle. 
Due to its influence on lipid and glutamine metabolism, SIRT4 has been linked to 
several diseases. For example, the suppression of SIRT4 may protect against 
type 2 diabetes. Indeed, mRNA levels in granulocytes and monocytes from normal 
and type 2 diabetes subjects revealed a negative association between SIRT4, 
plasma glucose, and high-density lipoprotein cholesterol, showing a potentially 
protective role of the inhibition of SIRT4 in type 2 diabetes[86]. Impairment in 
metabolism is also related to the development of many cancers, with genomic 
instability, and SIRT4 is suggested to act as a tumor suppressor. This is supported 
by studies showing SIRT4 KO mice to spontaneously develop various types of 
tumors[87]. 
 
SIRT5 is a class 3 sirtuin, present primarily in prokaryotes. It is highly expressed 
in tissues such as heart, skeletal muscle, brain, liver, and kidney. In SIRT5 knock-
out mice, there is a little alteration of the mitochondrial acetylation state. This 
suggests that SIRT5 acts only in very specific targets[88]. For example, Schlicker 
et al. found that SIRT5 deacetylases cytochrome c, an essential protein involved 
in apoptosis and oxidative phosphorylation. SIRT5 also regulates the urea cycle 
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by deacetylating and activating carbamoyl phosphate synthetase I (CPS1) to 
catalyze the detoxification of ammonia[89]. 
 
The involvement of sirtuins in neuroprotection is still unclear because 
contradicting results support that activation or inhibition of sirtuins may be 
protective depending on the cellular context and type of sirtuin. For example, 
dietary polyphenolic compounds protect against neurodegenerative diseases via 
the activation of several pathways, including sirtuins[90]. Resveratrol, a phenol 
contained in grapes, blueberries, raspberries, and peanuts was found to protect 
heart and brain from ischemic injury[91] via activation of the SIRT1. Resveratrol 
mimics ischemic preconditioning, a technique in which the induction of short 
ischemic events protects against a subsequent, more potent insult. Raval et al. 
showed that blocking SIRT1 through the use of sirtinol eliminated the protection 
induced by ischemic preconditioning[92]. On the other hand, Pallos and 
colleagues found that reducing the level of Sir2 by 50% protected photoreceptors 
expressing mutant Htt in flies from death[93]. Furthermore, alpha-synuclein 
toxicity is prevented when SIRT2 is inhibited and treatment with sirtuinol protects 
cultured cortical neurons against excitotoxicity. In Alzheimer disease, down-
regulation of the expression level of SIRT1 stimulates “nuclear factor kappa-light-
chain-enhancer of activated B cells” (NF-κB), which mediates inflammatory 
pathway and Aβ toxicity[94]. Finally, activation of SIRT1 by various flavonoids, 
such as kaempferol, quercetin, acacetin, apigenin, and luteolin, decreases 
neuroinflammation via NFkB repression[95]. Moreover, it was shown that the 
neuroprotective or neurotoxic effect of the resveratrol depends on the 
concentration used as reported by Della-Morte et al[96]. 
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1.5.5 Caenorhabditis elegans SIRTUINS  
In C. elegans, there are 4 sirtuins: sir-2.1, which shares 49% of identity with 
SIRT1, sir-2.2 and sir-2.3, homologs of SIRT4, and sir-2.4, the homolog of SIRT6. 
C. elegans and mammalian sirtuins also share the same intracellular localization, 
except for sir-2.4 that is cytoplasmic instead of being nuclear (fig.7) Although C. 
elegans sir-2.2 and sir-2.3 have been suggested to function during oxidative 
stress[97], their role in neurodegeneration remains largely uncharacterized.  
 
 sir-2.1 sir-2.2 sir-2.3 sir-2.4 
SIRT1 49%/67% 26%/43% 23%/42% 25%/38% 
SIRT2 43%/64% 26%/40% 25%/39% 24%/43% 
SIRT3 45%/65% 30%/42% 26%/40% 27%/41% 
SIRT4 29%/46% 50%/64% 43%/62% 23%/40% 
SIRT5 33%/49% 27%/42% 28%/45% 24%/36% 
SIRT6 23%/41% 23%/40% 24%/42% 37%/55% 
SIRT7 27%/44% 25%/42% 25%/40% 39%/49% 
Fig.6 Homologies and identities between mammalian and C. elegans sirtuins. 
 
 
Fig.7 Cellular localization mammalian and C.elegans sirtuins. 
 
The most studied C. elegans sirtuin is SIR-2.1. SIR-2.1 is the evolutionally closest 
sirtuin to mammalian SIRT1 and to the yeast SIR-2. An overexpression of sir-2.1 
leads to increase the lifespan by up to 50% through the involvement of multiple 
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pathways that converge on the regulation of the DAF-16, a forkhead transcription 
factor of the FOXO family, which is negatively controlled by the insulin/IGF-1 
pathway[84]. 
SIR-2.2 and SIR-2.3 are the homologous to the mammalian SIRT4 and are 
mitochondrial proteins[98]. A genome wide RNAi screen identified SIR-2.2 
together with many chromatin linked factors, DNA repair/replication proteins, and 
cell cycle/checkpoint proteins, to be needed for genome stability in somatic and 
germline cells. SIR-2.2 was found to protect C. elegans from neurodegeneration. 
However, SIR-2.2 and SIR-2.3 do not appear to be involved in longevity.  
 
1.6 CALORIC RESTRICTION 
Caloric restriction (CR) is the decrease in caloric intake by about 10-50%, without 
compromising the right balance of essential nutrients. CR is associated with an 
increase of lifespan, delaying the onset of age-related diseases[99]. The theory of 
CR is based on the hypothesis that there is an inverse correlation between the 
maximum lifespan of an organism and its metabolized nutritive energy. According 
to this, a decrease of the metabolic rate was found to result in an increase in 
longevity in drosophila and C. elegans[100]. Since the increase of the metabolism 
is related to an increase in the mitochondrial function, this may be associated to 
an increase of ROS. 
 
In response to food limitation or crowding, some animals are able to delay 
development and enter into a dormancy state known as diapause. C. elegans 
under dietary deprivation enter in a diapause state referred to as the dauer stage. 
C. elegans has been helpful in identifying signaling pathways during dauer 
formation. There are three main pathways involved in this phenomenon: cGMP, 
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TGF-β, and insulin-like signals. These act on the nuclear hormone receptor DAF-
12.  DAF-12, when it does not have bound insulin, triggers the development of the 
dauer stage through the activation of genes correlated with morphological 
modifications[101]. Calixto et al. showed that diapause entry inhibits neuronal 
degeneration. They showed that this is due to upregulation of anti-oxidative 
defense systems via activation of DAF-16/FOXO and SKN-1/Nrf-2. Indeed, it was 
found that DAF-16 activates the transcription of genes like superoxide dismutase-
3 (sod-3) and Catalase-2 (ctl-1), while SKN-1/Nrf-2 activates the phase 2 
detoxification enzymes[102]. 
 
Another way to induce CR is by inhibiting glycolysis. 2-Deoxy-D-glucose (2DG) is 
a glucose analogue that is taken up by the glucose transporters and is 
phosphorylated but that cannot be fully metabolized. Thus, 2-DG-6-phosphate 
accumulates in the cell and interferes with carbohydrate metabolism by inhibiting 
glycolytic enzymes. 2DG is a fully established glycolytic inhibitor which provides a 
physiological phenotype characteristic of CR but without notable effects on food 
intake. It was showed that 2DG protected fetal hippocampal cells against 
glutamate excitotoxicity[103]. Other studies showed that 2DG treatment could 
attenuate cerebral damage similar to the degree observed in CR in a model of 
focal ischemia. Schulz et al. showed that 2DG extends lifespan in C. elegans, via 
a mechanism dependent on AMPK signaling[104]. 
 
1.7 SIRTUINS IN CALORIC RESTRICTION 
Sirtuins promote longevity and delay aging via the regulation of key proteins like 
p53, FOXO, and Ku70, required in either apoptotic processes or cellular repair 
mechanisms. Sirtuins may also slow cell death or boost the repair mechanisms of 
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the cell. Several studies suggest that sirtuins mediate the effects of dietary 
regimen and caloric restriction[105]. The expression of SIRT1 enhances upon 
caloric restriction in rodents and human tissues, including the liver, skeletal 
muscle, kidney, adipose, and brain. 
The levels of NAD+ increase in liver cells under CR condition leading to activation 
of sirtuins including SIRT1. This may explain why the increases of NAD+ has been 
found to be protective for neurons. SIRT1 also activates peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α), which results in 
mitochondriogenesis that may counteract malfunctioning of the mitochondrial 
activity that is common to many age-related diseases[106]. 
 
1.8 OXIDATIVE STRESS AND MITOHORMESIS 
Mitochondria are important organelles responsible for providing energy to the cells 
through the generation of ATP and for producing intermediates of the Krebs cycle. 
Mitochondria release 90% of the ROS produced by the cell, mostly by oxidative 
phosphorylation. The balance between the production of ROS and its 
consumption must be kept in a physiologic range, as ROS are able to oxidize 
lipids, DNA, and proteins to cause irreversible damages. The cells prevent 
oxidation by ROS through antioxidant defense mechanisms that quench ROS, 
converting them in inert molecules[107]. Antioxidants could be divided into two 
categories: enzymatic and nonenzymatic. The major enzymes involved are 
superoxide dismutase (SODs), catalase, and glutathione peroxidase (GSH-Px). 
SODs are the most important because they are able to scavenge the superoxide 
that is the primary ROS produced by the cell. The nonenzymatic antioxidants 
include compounds such as vitamins C, E, beta-carotene, and GSH[108]. GSH is 
abundant in the cell and its ratio GSH/GSSG is the principal determinant of 
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oxidative stress. GSH is a cofactor for various detoxifying enzymes, such as GSH-
Px and transferase. It converts vitamin C and vitamin E to their active forms. GSH 
production is regulated by the nuclear factor erythroid 2-related factor (Nrf2)[109]. 
 
While it is generally accepted that high levels of ROS cause damage to the cells, 
low levels of ROS may instead improve the cellular response to a stressor, 
inducing an adaptive response[107]. This dualism, in which high amounts of ROS 
lead to damage, versus low levels of ROS that lead to protection, is known as 
mitohormesis[110]. 
 
Fig.8 Mitochondrial Hormesis (Mitohormesis) (Ristow, 2014).   
 
1.9 THE MODEL ORGANISM Caenorhabditis elegans  
The main challenge to the identification of effective treatments starts from an 
inadequate understanding of the many pathways involved in diseases. 
Mammalian disease models offer vast similarity to the human brain, but testing 
the therapeutic benefit of small molecules in mammalian models is extremely 
costly and time-consuming. In the past decades, C. elegans has increasingly been 
used as a model system to investigate the molecular mechanisms that contribute 
to increased neurodegeneration[111]. Due to its well-characterized and directly 
available nervous system, rapid life cycle (≈3 days) (Fig.9) and short lifespan 
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(≈3 weeks), easy genetic manipulation, unique behavioral and neuropathological 
defects, and a surprisingly high level of biochemical conservation compared to 
humans, C. elegans is a convenient and reliable model for the study of 
neurodegeneration. Extraordinary similarities exist between nematode and 
vertebrate neurons at the molecular and cellular levels. For example, classic 
neurotransmitters, ion channels, receptors, [serotonin, glutamate, γ-aminobutyric 
acid (GABA), acetylcholine, and dopamine (DA)], vesicular transporters, and the 
neurotransmitter release system are related in both structure and function 
between vertebrates and C. elegans[112]. Importantly, the impact of several 
difficulties, such as genetic mutations or exposure to drugs on the survival and 
function of neuronal populations in the C. elegans nervous system, can be quickly 
investigated in vivo[113]. 
 
 
Fig.9 C. elegans life cycle at 22˚C (artwork by Altun and Hall) 
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2. MATERIAL AND METHODS 
 
2.1 CAENORHABDITIS ELEGANS STRAINS AND GROWTH  
Nematodes were kept at 20°C on standard nematode growth medium (NMG) 
seeded with Escherichia Coli (strain OP50-) (Brenner et al., 1974) as food source. 
For experiments with 2-deoxy-glucose (2-DG), animals were grown on plates in 
which 2-DG was dissolved in the agar to a final concentration of 5 mM. All animals 
used in this study were hermaphrodites. Males were used for crosses only. Double 
mutants were generated by standard crosses. Mutations were followed through 
the crosses by PCR and sequencing.  
 
The following C. elegans strains were used in this study: Wild-type N2 Bristol, 
zdls5 [pmec-4::GFP] I to label touch neurons with GFP, VC199 (zdls5 [pmec-
4::GFP] I; mec-4(u231) X), IS111 (EX [MEC-10(A673T);pmec-4::mcherry),  
RB654 (sir-2.3(ok444) X), BLC231 (sir-2.3(ok444) X ;EX[zdls5 (pmec-4::GFP) I; 
mec-4(u231) X]), BLC320 (sir-2.1(ok434) IV; sir-2.3(ok444) X; EX[zdls5 (pmec-
4::GFP) I; mec-4(u231) X]), BLC230 (sir-2.3(ok444) X; EX [MEC-
10(A673T);pmec-4::mcherry) X::GFP]), MH1090 (pnc-1(uk212) IV), BLC298 (sir-
2.3(ok444) X ;EX[zdls5 (pmec-4::GFP) I; mec-4(u231) X]; EX[SIR-2.3]; unc-
122::GFP), ZB164 bzIs8 (pmec-4mec-4::GFP) and BCL314 (sir-2.3(ok444) X; pmec-
4mec-4::GFP). In sir-2.1(ok434) and sir-2.3(ok444), 768 bp (from nucleotide 501 
to nucleotide 1268) and 839 bp (from nucleotide 501 to nucleotide 1340) 
respectively are deleted.  
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2.2 MOLECULAR BIOLOGY 
For the sir-2.3 rescue construct, the 3700 bp sir-2.3 genomic DNA sequence was 
amplified from N2 genomic DNA using primers  
5’-GGATCCCGGAACTTCATGGCAGTGCTCTTCAAGTA-3’ and 5’-
GGTACCTGACATTTCTTTCAAAACATCCGAAATTCTGTAGTCTAACTTCATT-
3’   that added BamHI and KpnI restriction sites to the 5’ and 3’ ends, respectively. 
sir-2.3 genomic DNA was then cloned into pPD95.75 with the sir-2.3 promoter. 
Germline transformation by microinjection was performed as described (Mello et 
al., 1991). 
 
2.3 NEMATODE SYNCHRONIZATION 
Gravid adults were collected in a 1.5 ml eppendorf tubes and treated with 200 µl 
of bleach and 80 µl of 10M NaOH in 700 µl of water for ~ 7 min to release the 
eggs. After centrifugation for 3 min at 3000 rpm and removal of the supernatant, 
eggs were resuspended in 100 µl of sterile water, prior to inoculation onto seeded 
NGM plates. 
 
2.4 FLUORESCENT MICROSCOPY 
Animals were mounted on thin agarose pads and immobilized by 20 mM Na-azide. 
Fluorescent micrographs were taken using a LEICA DMR2 fluorescent 
microscope equipped with 40X and 63X objective, a Spot RT slider camera 
(Diagnostic Instruments) equipped with Spot32 acquisition software, a LEICA 
green fluorescent protein (GFP) plus filter (460/480 nm excitation filter) and a 
LEICA rhodamine filter (535/550 nm excitation filter). For strict quantitative 
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comparisons, images were acquired using the same exposure time; images were 
analyzed and processed using ImageJ.  
 
2.5 CHEMICALLY INDUCED ISCHEMIA AND QUANTIFICATION 
OF NEURONAL DEATH 
For chemical induced ischemia, synchronized adult worms were exposed for 5h 
at 22°C to the following solutions: 1) S Basal at pH 6.5 (for 100 ml of solution: 
0.584 g NaCl, 0.1 g K2HPO4, 0.6 g KH2PO4, Acetic Acid 57 µl); 2) S Basal at pH 
6.5 plus 100 mM Sodium Azide.  After treatment, worms were allowed to recover 
onto fresh NGM plates for 20 hours at 20°C and then stained with DiD (Swanson 
RA et al.,1997, Scott BA at al., 2002). Animals were visualized under a 40X 
objective using rhodamine filters and DiD stained amphid sensory neurons were 
counted in each animal.  
For quantification of neuronal death in mec-4(d) and mec-10(d) strains, GFP or 
mcherry expressing touch neurons were counted in synchronized L4-staged 
animals, and swollen PLM touch neurons were counted in synchronized L1-
staged animals. 
  
2.6 CAENORHABDITIS ELEGANS EMBRYONIC CELL CULTURE 
Embryonic cell culture was performed as described previously (Sangaletti and 
Bianchi, 2013). Briefly, a large number of gravid adult worms were grown on 
enriched peptone agar plates (8P) with NA22 Escherichia Coli, collected in 50 ml 
tubes, washed 3 times with sterile H2O and centrifuged at 1200 rpm for 10 
minutes. After removal of the supernatant, nematodes were transferred into 15 ml 
tubes and lysed with 5-6 ml of lysing solution (5 ml of fresh bleach, 1.25 ml of 10N 
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NaOH and 18.5 ml of sterile H2O) for 5-10 min. The lysis was stopped by adding 
egg buffer (118 mM NaCl, 48 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 25 mM Hepes, 
pH 7.3, 340 mOsm) to the tube. Lysed animals were then centrifuged for 10 
minutes at 1,200 rpm. Eggs were separated from the animal carcasses using 2 ml 
of egg buffer plus 2 ml of 60% sucrose and centrifuged for 20 min at 1,200 rpm. 
Eggs floating at the top of the tube were collected in a new 15 ml tube with a 
P1000 pipetor, washed 3 times with fresh egg buffer and centrifuged for 10 min at 
1,200 rpm. To dissociate the embryonic cells, eggs were incubated for 10-30 
minutes with 1 ml of 2 mg/ml Chitinase (Chitinase from Streptomyces Griseus- 
Sigma Aldrich, C6137-25UN) dissolved in egg buffer pH 6.5. After enzymatic 
treatment, embryos were pelleted by centrifugation for 3 min at 2,500 rpm. The 
supernatant was removed and the eggs were resuspended in L-15 medium (L-15 
culture medium form Gibco, 10% Fetal Bovine Serum, 45 mOsm Sucrose, 1 U/ml 
Penicillin and 100 µg/ml Streptomycin). Cells were manually dissociated using a 
10 ml syringe equipped with a 18 Gauge needle. The suspension containing cells 
and debris was subsequently filtered using a sterile 5 µM Millipore filter. Filtered 
cells were pelleted for 3 min at 2,500 rpm and resuspended in fresh L-15 medium. 
Cells were plated at ~230,000 cell/cm2 density in 24 wells plates on microscope 
slides (12 mm diameter) previously coated with 0.5 mg/ml peanut lectin (Sigma 
Aldrich, L0881-10MG). The media was replaced the day after and the cells were 
kept at 20°C for up to 7-9 days. To quantify the number of GFP touch neurons 
alive cells were fixed using the following protocol: the medium was removed and 
cells were washed three times with physiological solution (145 mM NaCl, 5 mM 
KCl, 1 mM CaCl2, 5 mM MgCl2, 10 mM Hepes, 20 mM D-glucose, 25 mM sucrose, 
pH 7.2, and 345 mosmol/kgH2O). Cells were then fixed for 15 min with 4% 
paraformaldehyde dissolved in physiological solution and washed three times with 
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egg buffer. Coverslips were mounting using Vectashield mounting medium and 
photographed using a 63X oil objective and GFP filter as described above. 
 
2.7 QUANTITATIVE REAL-TIME PCR 
RNA was extracted from synchronized young adult worms using TRIzol reagent 
(invitrogen), following manufacture’s procedures, after 5 washes with sterile water. 
cDNA was synthesized using the High capacity RNA-to-cDNA Kit (Applied 
Biosystem). qRT-PCR was carried out using Taqman Universal Master Mix II 
(Applied Biosystem) and the average mRNA fold change of each target gene was 
calculated by comparing the CT (cycle threshold) of the target gene to that of the 
housekeeping gene pmp-3. All reactions had three technical replicates and each 
condition had three biological replicates. 
The Taqman probes span an exon junction: sir-2.1 (3-4, 3-5), sir-2.2 (5-6), sir-2.3 
(5-6), sir-2.4 (2-3), pmp-3 (3-4, 4-5). Relative quantification was with the ΔΔCT 
method (2(−ΔΔCT)), and P values were calculated by t test. The wild type was 
used as the calibrator to assess fold change in gene expression.  
 
2.8 QUANTIFICATION OF ROS 
ROS levels were quantified in WT (N2) and RB654 sir-2.3(ok444). Adult C. 
elegans nematodes were divided into two groups: starved for 48h in absence of 
food and fed with Escherichia Coli (strain OP50-). The animals were incubated 
with 50µM H2-DCFDA (Sigma-Aldrich) for 1h under shacking condition at room 
temperature. The working solution 100µM in M9 was made from a 50mM stock 
solution in DMSO. The fluorescence of each worm was measured trough a 
fluorescent microscope LEICA DMR2 at Ex/Em 495/527 nm after immobilization 
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of the worms with NaAzide 20mM with the same exposure time (800ms). The 
analysis of the intensity of the fluorescence was performed with ImageJ. 
 
2.9 SAMPLE SIZE AND DATA REPLICATION 
In Figure 1, 300 adult animals were used for panel C-F. N of experiments was 1 
for panel C and D, 3 for panel E and 1 for panel F. Each RT-PCR experiment was 
replicated 3 times. In panel G N=50 adult animals analyzed for each condition. 
The experiment was replicated 4 times in the laboratory. In Figure 2 panel A-D, N 
was 23 experiments for mec-4(d) and mec-4(d);sir-2.3 and 4 for mec-4(d);sir-
2.3;SIR-2.3. 50 animals per strain were analyzed in each experiment. Panel E-H 
N=4 experiments, using at least 50 animals per strain in each experiment. Panel 
J number of experiments was 5 for mec-4(d) and mec-4(d);sir-2.3(ok444) and 4 
for mec-4(d);sir-2.3(ok444);SIR-2.3. 50 animals per strain were analyzed in each 
experiment. In Figure 3 number of animals for wild-type were 24 and 25, for pnc-
1(ku212) mutant were 23 and 25 in control condition and azide respectively. The 
experiment was replicated 3 times. In Figure 4, panel A-D number of animals was 
30 in each experiment and condition. The experiment was replicated 4 times. In 
Figure 5 panel G, N=2 coverslips per each strain (wild-type, mec-4(d) and mec-
4(d);sir-2.3(ok444)) and condition (control and 10 mM 2-DG). 10 fields were 
scored for each coverslip. The experiment was repeated 5 times. Panel H N=2 
coverslips per each strain and condition (See detail in Figure legends section). 10 
fields were scored for each coverslip. In Figure 6 panel A, number of animals was 
(from left to right) 22, 55, 23, 68, 25, 23, 23, 16, 38 and 35 obtained from 12 
experiments. In Suppl. Figure 1 panel A, N= 300 adult animals. The experiment 
was replicated 3 times. Panel B, N=3 experiments using at least 30 animals for 
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each strain. Suppl. Figure 2 Panel C N= 30 animals for each strain. The 
experiment was replicated 3 times. 
 
2.10 STATISTICS 
We used Origin version 6.1 and 9 for calculation of statistical analysis. Differences 
between two groups were assessed using two-sample t-Test. Anova with 
Bonferroni’s multiple comparison test was used to compare more the two groups. 
All p-values <0.05 were considered significant. Statistical analysis and P values 
are listed in detail at the end of each figure legends.   
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3. RESULTS 
3.1 LONG LASTING PROTECTION OF DIAPAUSE AGAINST mec-
4(d) AND mec-10(d) INDUCED NEURONAL DEATH 
MEC-4 and MEC-10 are DEG/ENaC proteins that form the pore of the channel 
complex. Mec-10 is 53% identical to mec-4 with which it coassemble to form a 
heteromultimeric channel complex in C. elegans touch neurons [114]. Mec-4(d) is 
a mutation that causes a dramatic death of C. elegans touch neurons by 
hyperactivation of Na+/Ca2+ channel MEC-4 (mec-4(d)). Mec-10(d) is a mutation 
that causes only a mild degeneration when hyperactivated. While mec-4 is the 
main channel subunit, mec-10 functions as a modulatory subunit [114-117]. There 
are six touch neurons in C. elegans: two anterior lateral microtubule cells (ALMs), 
one anterior ventral microtubule cell (AVM), two posterior lateral microtubule cells 
(PLMs) and one posterior ventral microtubule cell (PVM).  
We quantified the extent of neurodegeneration counting the number of surviving 
GFP-expressing touch neurons in L4 larval stage in transgenic lines labeled by 
GFP (Pmec-4::GFP) in which the GPF is expressed only in the touch neurons. 
 
We found that at the L4 larval stage 0.36 +/- 0.02 ratio of the mec-4(d) animals 
have no surviving touch neurons, 0.38 +/- 0.02 ratio have one surviving touch 
neuron and 0.24 +/- 0.03 ratio have 2 surviving touch neurons which in most cases 
are AVM and PVM (Fig. 1 A-E). 
Calixto and colleagues showed that diapause entry called dauer state, in C. 
elegans protects touch neurons against mec-4(d) induced neuronal death and that 
the protective effect lasts for hours after exit from the dauer state [102]. 
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 We confirmed these results by finding that 16 hours after dauer exit, the ratio of 
L4 animals with 0 surviving touch neurons is 0.08 +/- 0.02, the ratio with 1 surviving 
touch neurons is 0.31 +/- 0.04 and the ratio with 2 surviving touch neurons is 0.45 
+/- 0.03. In 0.14 +/- 0.04 ratio of animals that have spent time in diapause, we 
found 3 surviving touch neurons (an ALM or a PLM, rarely 2 ALMs or 2 PLMs), 
which we never observed in mec-4(d) L4 animals grown in the presence of food 
(Fig. 1 A-E).  
 
Fig. 1. Having been in dauer state is protective against mec-4(d) and mec-10(d)-induced 
neuronal death. A: Schematic drawing of a C. elegans with the location of the 6 touch 
neurons that express mec-4 (2 ALMs, AVM, 2 PLMs and PVM). In mec-4(d), the two neurons 
that usually survive are AVM and PVM (shown in green). B-E: Ratio of mec-4(d) animals 
continuously grown in the presence of food and recovered from the dauer state (labeled a 
“starved”) that have either no surviving, or 1, 2 or 3 surviving touch neurons. N of experiments 
was 3 and 5 respectively, with at least 50 animals analyzed per experiment. F: mec-4 
homologous subunit mec-10 is expressed in touch neurons also. Shown in green are the 
neurons that survive in animals that express the transgene of the hyperactive mutant mec-
10(d). G-J: same as in B-E for mec-10(d) expressing animals. N of experiments was 4 for 
both, with at least 50 animals analyzed per experiment. Data are expressed as mean +/- SE. 
* and ** indicate P£ 0.05 and 0.01 respectively by Student’s t-test. 
 
To test whether the protective effect afforded by diapause entry is more robust 
under less toxic conditions, we compared the extent of touch neurons 
degeneration in animals expressing mec-10(d) transgene grown under control 
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conditions and 16 hours after dauer exit. In line with its modulatory role in channel 
function, mec-10 causes only mild degeneration when hyperactivated by mutation 
A673T corresponding to A713V/T in mec-4 [114, 116]. We found that diapause 
was protective in mec-10(d) induced neuronal death to a similar extent as it is 
protective in mec-4(d) (Fig. 1 F-J). Indeed, the ratio of L4 animals with 4, 5 and 6 
surviving touch neurons is 0.20 +/- 0.05 and 0.02 +/- 0.01, 0.43 +/- 0.03 and 0.25 
+/- 0.06, and 0.28 +/- 0.06 and 0.70 +/- 0.07 for animals grown under standard 
conditions and animals recovered from dauer respectively. These results are in 
line with the results reported by Calixto and colleagues [102] and show that 
cellular/organismal protective modifications that occur when the animal enters into 
diapause are maintained for at least 16 hours after dauer exit. These data also 
show that comparable effects mediated by entry in diapause are present under 
both strong and mild toxic insults [118]. 
 
3.2 KNOCK-OUT OF A MITOCHONDRIAL SIRTUIN IS 
PROTECTIVE AGAINST NEURONAL DEATH 
Sirtuins are NAD+-dependent deacethylases and mono-ADP-ribosyltransferases 
that link nutrient availability/cellular metabolism to aging, cancer growth and 
neurodegeneration Qin, 2006 [63, 119-123]. We thus, hypothesized that sirtuins 
might be involved in the protective effect mediated by diapause. To test this 
hypothesis, we first wanted to establish whether the mRNA of sirtuins is regulated 
in conditions that promote neuronal death. To this end, we established a protocol 
to induce ischemia in the whole animal, from which we then extracted mRNA to 
perform real time RT-PCR experiments. 
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Chemical ischemia was induced by incubation of C. elegans in 100 mM azide at 
pH 6.5, followed by a recovery period [58, 124]. Azide blocks complex IV of the 
electrontransport chain, blocking ATP production and consequently causing cell 
death by necrosis [125]. To confirm that this protocol was effective in inducing 
neuronal death, we stained treated animals with the lipophilic dye DiD. DiD is 
taken up by neurons that are exposed to the outside environment, including 
amphid sensory neurons.    
There are 12 amphid sensory neurons, 11 of which are chemosensory neurons 
(ADF, ADL, ASE, ASG, ASH, ASI, ASJ, ASK, AWA, AWB, AWC) which C.elegans 
use to sense chemicals. The twelfth, AFD, is a thermosensory amphid neuron. As 
a result of what these tiny animals sense, they can either decide to move toward 
the chemical (as with chemical attractants), away from the chemical (as with 
chemical repellants), or not at all (Bargmann CI 2006). 
 
The uptake of the fluorescent dye requires retrograde transport and therefore it 
does not occur in dead or sick neurons [126]. In animals incubated in buffer at pH 
6.5, all 12 amphid sensory neurons are stained with DiD (Fig. 2A). Conversely, in 
animals treated with azide an average of 1 amphid sensory neuron per animal is 
stained (Fig. 2B), confirming that this treatment causes neuronal demise and likely 
the demise of other cells in the animal. Importantly, we found that also in this 
model limiting dietary deprivation protects against neuronal death, as many more 
amphid sensory neurons survive azide treatment in animals that have been in 
diapause. 
 
To test the effect of chemical ischemia on the transcription of sirtuin genes, we 
extracted mRNA from the treated animals every hour for the length of the 5 hours 
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treatment and performed real time RT-PCR. We found that while the mRNAs of 
sir-2.1 and sir-2.4 were relatively stable during azide treatment, the mRNA of sir-
2.2 has a peak of transcription after 2 hours of treatment and the mRNA of sir-2.3 
is elevated throughout the 5 hours of azide treatment, reaching about twice the 
amount after 5 hours (Fig. 2 C-F). Both sir-2.2 and sir-2.3 are localized in 
mitochondria and share the highest similarity with mammalian mitochondrial 
SIRT4 (50% and 42% identity, and 64% and 63% similarity, respectively) [85]. 
Given that the mRNA of sir-2.3 is elevated throughout the azide treatment, we 
focused on this sirtuin and wondered whether sir-2.3 might be involved in cell 
death induced by azide treatment. To test this possibility, we acquired sir-2.3 
knock-out mutants (sir-2.3(ok444)) [85] and quantified amphid sensory neurons 
DiD uptake in these animals following azide treatment. Surprisingly, we found that 
a significantly higher number of amphid sensory neurons survived in sir-2.3 knock-
out mutants versus wild type (3.36 +/- 0.87 and 0.74 +/- 0.21 for sir-2.3 and wild 
type respectively) (Fig. 2 G). The protective effect of knock-out of sir-2.3 likely 
extends to other cells in the animal as fewer sir-2.3 animals die when treated with 
azide (0.65 +/- 0.08 ratio of wild type animals die, 0.33 +/- 0.12 ** of sir-2.3 knock-
outs, and 0.57 +/- 0.07 for sir-2.3; SIR-2.3 rescue animals, 3 experiments with at 
least 50 animals per experiment, ** indicates p≤0.01 by ANOVA with Bonferroni 
correction). To confirm that the effects of sir-2.3 knock-out is mediated by the lack 
of this gene, we quantified amphid sensory neurons DiD uptake in rescue animals 
in which sir-2.3 was reintroduced under the control of its own promoter in the sir-
2.3 knock-out background. As expected for a gene specific effect, the number of 
amphid sensory neurons that are stained is restored to typical levels found in wild 
type background in sir-2.3;SIR-2.3 animals.  
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Fig. 2. The messenger RNA of mitochondrial SIR-2.3 is elevated and its knock-out is 
protective in a model of hypoxic ischemia. A: Photograph of the head of a wild type C. 
elegans incubated in S Basal at pH 6.5 for 5 hours and stained with the lipophilic dye DiD. 
DiD is taken up by 6 pairs of amphid sensory neurons (ASKs, ADLs, ASIs, ASHs, ASJs, and 
AWBs) exposed to the outside environment. B: Photograph of an animal treated with 100 mM 
azide at pH 6.5 for 5 hours and stained with DiD. Fewer stained sensory neurons are visible 
in this animal as a result of neuronal death. Scale bar is 20 µm. C-F: Relative (compared to 
pmp-3 housekeeping gene) abundance of mRNA of the 4 C. elegans sirtuins in animals 
treated for 5 hours with 100 mM azide. N of experiments was 1 for sir-2.1, 1 for sir-2.2, 3 for 
sir-2.3 and 1 for sir-2.4. In each experiment RT-PCR was done in triplicate. G: Number DiD 
stained amphid sensory neurons in wild type, wild type under dietary deprivation (DD), sir-2.3 
knock-out animals and sir-2.3;SIR-2.3 rescue animals incubated for 5 hours in S Basal at pH 
6.5 and in S Basal at pH 6.5 containing 100 mM Na-azide. The number of experiments was 4 
with at least 50 animals analyzed per experiment. Data are expressed as mean +/- SE. P 
were 0.01 and 0.0015 by ANOVA with Bonferroni correction. 
 
Given the documented role of sirtuins in providing protection against ageing and 
degenerative diseases, we wondered whether the knock-out of sir-2.3 causes 
compensatory increase of expression of another sirtuin gene, which in turn would 
provide protection against neuronal death. To test this possibility, we performed 
real time RT-PCR on mRNA extracted from sir-2.3(ok444) mutants. We found no 
change in mRNA level for the other 3 sirtuins (Fig. 3). 
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Fig. 3: Sirtuins mRNA in sir-2.3 knock-out (A) and sir-2.3;SIR-2.3 rescue strains (B): 
Quantitative real-time PCR (qRT-PCR) from total RNA in sir-2.3 strain was conducted using 
Taqman gene expression assays in order to quantify the levels of mRNA for sirtuin genes. 
mRNA percentage of each target gene was calculated by comparing the CT (cycle threshold) 
of the target gene to that of the housekeeping gene pmp-3. The wild-type N2 (Bristol) strain 
was used as the calibrator. All conditions had three technical replicates.  
 
 
 Furthermore, in sir-2.3;SIR-2.3 rescue animals, the mRNA of sir-2.3 is 
overexpressed as expected for a non-integrated transgenic C. elegans strain, yet 
there is no change in the extent of neuronal death, even for shorter incubation 
times with azide which cause less cell death, suggesting that over expression of 
this mitochondrial sirtuin does not provide protection. A similar conclusion can be 
drawn in the case of sir-2.2 whose mRNA is also elevated in sir-2.3;SIR-2.3 
animals. 
 
To conclude these data suggest that knock-out of mitochondrial sirtuin sir-2.3 in 
C. elegans is protective against cell death caused by chemical ischemia, a 
surprising result given that activation of sirtuins has been previously suggested to 
provide protection against ageing and degenerative conditions [62, 63, 119-122]. 
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3.3 KNOCK-OUT OF sir-2.3 IS PROTECTIVE IN HYPERACTIVE 
MEC CHANNEL INDUCED NEURONAL DEATH 
mec-4(d) and mec-10(d)-induced touch neurons degeneration shows all the 
hallmarks of necrotic cell death including elevation of intracellular Ca2+ and 
activation of Ca2+-sensitive calpains and cathepsins [54, 116, 127, 128]. We thus 
reasoned that knock-out of sir-2.3 might be protective in hyperactive mec channel 
induced cell death as well. To test this prediction, we crossed sir-2.3 knock-out 
with mec-4(d) and mec-10(d) strains and quantified touch neurons degeneration 
in L4 larvae. Consistent with the results in animals treated with azide (Fig. 2 G), 
more touch neurons survive in sir-2.3 knock-out animals than they do in animals 
in which sir-2.3 gene is wild type, when either mec-4 or mec-10 are hyperactivated 
[49, 116]. More specifically, the ratio of mec-4(d) animals that have no surviving 
and 2 surviving touch neurons went from 0.27 +/- 0.03 and 0.25 +/- 0.02, to 0.12 
+/- 0.01 and 0.43 +/- 0.03 in sir-2.3 knock-out animals (ratio of animals with 1 
surviving touch neuron remained unchanged). The effect is gene-specific, as the 
extent of neuronal death is restored to control levels in mec-4(d);sir-2.3;SIR-2.3 
rescue strain (ratio of animals with 0 and 2 surviving touch neurons was 0.24 +/- 
0.05 and 0.22 +/- 0.06 respectively, Fig. 4 A-D). Similarly, the ratio of mec-10(d) 
animals that have 4 and 6 surviving touch neurons went from 0.20 +/- 0.05 and 
0.28 +/- 0.06, to 0.01 +/- 0.01 and 0.65 +/- 0.03 in sir-2.3 knock-out animals (no 
change was observed in the ratio of animals with 5 surviving touch neurons) (Fig. 
4 E-H).  
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Fig. 4. Knock-out of mitochondrial sir-2.3 protects against mec-4(d) and mec-10(d)-
induced neuronal death. A-D: Quantification of the ratio of animals with 0, 1, 2 and 3 
surviving touch neurons in mec-4(d), mec-4(d);sir-2.3 knock-out and mec-4(d);sir-2.3;SIR-2.3 
rescue strains. Number of experiments was 23, 23 and 4, with at least 50 animals per strain 
analyzed in each experiment. P was 0.0002 and 0.0001 by ANOVA with Bonferroni correction. 
E-H: Ratio of mec-10(d) expressing animals with 3, 4, 5 and 6 surviving touch neurons. 
Number of experiments was 4 each, with at least 50 animals per strain analyzed in each 
experiment. P was 0.01 and 0.0024 by t-Test. I: Photograph of a tail of an L1 mec-4(d) mutant 
C. elegans showing a necrotic swollen PLM touch neuron, visible as a large vacuole. Scale 
bar is 10 µm. J: Quantification of the number of swollen PLMs in L1 mec-4(d), mec-4(d);sir-
2.3 knock-out and mec-4(d);sir-2.3;SIR-2.3 rescue strains. Number of experiments was 5, 5 
and 4, with at least 50 animals per strain analyzed in each experiment. Data are expressed 
as mean +/- SE. P was 0.014 by ANOVA with Bonferroni correction. 
 
Mec-4(d) begins to cause toxicity in touch neurons as soon as it becomes 
expressed early in development and at the first larval stage L1 touch neurons 
already show the signs of necrotic cell death as they appear swollen and filled with 
fluid (Fig. 4 I) [49]. To establish whether knock-out of sir-2.3 affords protection at 
these early developmental stages, we examined touch neurons in L1 larvae. We 
counted the number of PLM vacuoles in mec-4(d), mec-4(d);sir-2.3 and mec-
4(d);sir-2.3;SIR-2.3 rescue and found that there were fewer swollen PLM touch 
Figure	2,	Sangaletti	et	al.
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neurons in sir-2.3 knock-out animals (0.75 +/- 0.07 versus 1.2 +/- 0.12 in mec-4(d) 
and 1.35 +/- 0.13 in mec-4(d);sir-2.3;SIR-2.3, respectively). These results support 
that the protective effects of knock-out of mitochondrial sir-2.3 are present early 
on in development suggesting that the mechanisms involved are likely not grossly 
developmentally regulated. To rule out an effect of the knock-out of sir-2.3 on mec-
4(d) expression level in touch neurons, which would result in changes on the 
extent of neuronal death, we quantified fluorescence in touch neurons expressing 
GFP tagged MEC-4. We found that the knock-out of sir-2.3 does not change the 
level of expression of MEC-4::GFP transgene (Fig.5). Taken together these 
results support that knock-out of sir-2.3 provides protection against necrotic cell 
death induced by channel hyperactivation. 
 
Fig. 5: Similar levels of expression of a MEC-4::GFP transgene in wild type and sir-2.3 
knock-out animals. A and B: Representative photographs of tails of transgenic wild type (A) 
and sir-2.3(ok444) (B) animals expressing MEC-4::GFP in PLM’s touch neurons. Scale bar is 
20 µm. C: Quantification of MEC-4::GFP intensity in PLM’s, PVM, ALM’s and AVM touch 
neurons of N2 and sir-2.3(ok444) animals. N= 30 and 34 pmec-4mec-4::GFP and sir-
2.3(ok444); pmec-4mec-4::GFP animals, respectively. 
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3.4 BLOCK OF THE NICOTINAMIDE ADENINE DINUCLEOTIDE 
(NAD) SALVAGE PATHWAY PROTECTS AGAINST NEURONAL 
DEATH 
Sirtuins use NAD+ as substrate in their de-acetylation reaction. NAD+ is both 
synthesized de novo from tryptophan and by recycling of degraded NAD+ products 
such as nicotinamide through the salvage pathway (Fig. 6 A) [129, 130]. A key 
enzyme of the NAD+ salvage pathway in invertebrates is the nicotinamidase 
encoded by the PNC1 gene (pnc-1 in C. elegans), which converts nicotinamide 
into nicotinic acid [131, 132]. Inhibition or knock-out of pnc-1 reduces the level of 
NAD+ and increases the concentration of nicotinamide in the cell, as this pnc-1 
substrate is no longer metabolized. The end result of both these effects is 
inhibition of sirtuins as nicotinamide functions in a negative feedback loop to inhibit 
sirtuins function [133].  
 
Fig. 6. Block of the NAD+ salvage pathway by null mutation in pnc-1 protects neurons 
from hypoxic ischemia. A: schematic representation of the invertebrate NAD+ salvage 
pathway. In invertebrates PNC-1 converts nicotinamide into nicotinic acid. A null mutation in 
pnc-1 leads to reduced availability of NAD+ and accumulation of its substrate nicotinamide, 
which in turn inhibits the activity of sirtuins. B: Average number of DiD stained amphid sensory 
neurons in WT and pnc-1(ku212) mutant in control conditions (pH 6.5) and under conditions 
of chemical hypoxia (100 mM azide at pH 6.5). Data are expressed as mean +/- SE. Number 
of animals was 24 and 25 for wild type and 23 and 25 for pnc-1(ku212) in control conditions 
and azide respectively.  P was 0.000029 by Student’s t-test. 
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We thus reasoned that blocking the NAD+ salvage pathway may produce the 
same effect on neuronal death as the knock-out of sir-2.3. To test this hypothesis, 
we acquired the pnc-1(ku212) mutant, which encodes a premature stop mutation 
in both pnc-1a and pnc-1b isoforms leading to complete loss of enzymatic activity 
[134]. Pnc-1(ku212) mutants have developmental defects in the reproductive 
system, including delayed development of the gonad and necrosis of the four 
uterine cells, and they are egg-laying defective [134, 135]. Contrarily to what it 
may have been expected from the necrosis of the uterine cells in pnc-1(ku212) 
mutants, when we quantified the number of amphid sensory neurons that uptake 
DiD in pnc-1(uk212) animals treated with azide, we found that they were more 
than in wild type (2.58  +/- 0.34 versus 0.68 +/-  0.23, Fig. 6 B). We interpret these 
results to suggest that inhibition of the activity of sirtuins via reduced NAD+ and 
increased nicotinamide in pnc-1(ku212) is protective in cells under ischemic insult, 
which is consistent with data shown in Fig. 2 and 4. 
 
3.5 BLOCK OF GLUCOSE METABOLISM REDUCES mec-4(d) 
INDUCED NEURONAL DEATH 
We showed that the protective effect of diapause and knock-out of sir-2.3 are 
quantitatively similar. To learn more about the nature of the mechanisms 
underlying these protective effects, we first turned to the use of 2-Deoxy-D-
glucose to control worm metabolism. 2-Deoxy-D-glucose (2-DG) is a glucose 
analogue that is taken up by the glucose transporters and is phosphorylated but 
that cannot be fully metabolized. Thus, 2-DG-6-phosphate accumulates in the cell 
and interferes with carbohydrate metabolism by inhibiting glycolytic enzymes. We 
tested the effect of 2-DG on mec-4(d)-induced neuronal death by culturing worms 
on plates containing 10 mM 2-DG. We found that that in mec-4(d) animals cultured 
 68 
in these conditions, neuronal death is reduced. While the ratio of animals with 1 
surviving touch neuron remained unchanged, the ratio of animals with 0 and 2 
surviving touch neurons went from 0.31 +/- 0.04 and 0.21 +/- 0.03 for animals 
cultured on standard plates to 0.22 +/- 0.08 and 0.45 +/- 0.07 for animals cultured 
on 2-DG plates respectively (fig. 7 A-D). Importantly, surviving neurons appeared 
also healthier as they retained at least part of their neuronal processes (Fig. 7 E). 
Thus, block of glycolysis provides protection against mec-4(d)-induced neuronal 
death. 
 
Fig. 7. Protection afforded by block of glycolysis in the presence and absence of SIR-
2.3. A-D: Ratio of animals with 0, 1, 2 or 3 surviving touch neurons that were either grown on 
standard plates or on plates containing 5 mM 2-DG for 48 hours. Number of experiments was 
4 each, with at least 30 animals in each experiment. Data are expressed as mean +/- SE. P 
was 0.0012, 0.018 and 0.048, by t-Test. E: Photograph of a ALM touch neuron in a mec-4(d) 
animals grown on 2-DG plate. The neuronal processes are still intact and show some 
arborization. Scale bar is 10 µm. 
 
Calixto and colleagues showed that the protective effect of diapause and caloric 
restriction on mec-4(d)-induced touch neurons degeneration is mediated by the 
Insulin/IGF-1-like signaling pathway via activation of antioxidant mechanisms. Our 
results support that treatment with 2-DG mimics the protective effects of diapause. 
We also found that knock-out of mitochondrial sirtuin sir-2.3 mediates a similar 
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level of protection in mec-4(d), mec-10(d) and azide mediated cell death. Thus, 
we next wondered whether the protection afforded by 2-DG treatment and knock-
out of sir-2.3 is mediated by the same mechanisms. To test this possibility, we 
treated mec-4(d);sir-2.3 mutants with 2-DG and compared the extent of cell death 
with untreated animals and with mec-4(d) animals treated with 2-DG. We found 
that 2-DG enhances protection in mec-4(d);sir-2.3 beyond the level seen in 
untreated animals and in mec-4(d) animals treated with 2-DG (ratio of animals 
with 0, 1 and 2 surviving touch neurons in mec-4(d);sir-2.3 was 0.11 +/- 0.04, 0.28 
+/- 0.02 and 0.60 +/- 0.05 respectively Fig. 7 A-D). These results support that 2-
DG and knock-out of sir-2.3 mediate protection through two different mechanisms.  
 
3.6 EXPERIMENTS IN CELL CULTURE REVEAL A CELL 
AUTONOMOUS EFFECT OF 2-DG DEPENDENT ON KNOCK-OUT 
OF sir-2.3 
The protection of touch neurons degeneration mediated by diapause entry in mec-
4(d) animals is via the insulin/IGF-1-like signaling pathway involving the insulin 
receptor daf-2 and therefore is non-cell autonomous. However, it is unclear 
whether protection mediated by sir-2.3 knock-out is cell-autonomous or not. To 
test the dependence of protection afforded by knock-out of sir-2.3 on other 
tissues/cells, we performed experiments in cell culture, where cell to cell contacts 
are rare and where substances released by other cells are significantly diluted in 
the culturing media. 
 
C. elegans embryonic cells can be dissociated and cultured in vitro where they 
differentiate and express cell specific markers. We have previously shown that 24 
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hours after plating, C. elegans touch neurons are differentiated and 
morphologically resemble touch neurons in vivo, express GFP under the control 
of mec-4 promoter and undergo cell death when they express mec-4(d). We 
cultured C. elegans embryonic cells from wild type, mec-4(d) and mec-4(d);sir-
2.3(ok444) both in control conditions and in the presence of 2-DG. Touch neurons 
were labeled by expression of GFP under the control of the mec-4 promoter (Fig. 
8 A-F). We thus quantified the ratio of touch neurons under the two culturing 
conditions for all three genetic backgrounds. As expected, we found that touch 
neurons make up ~5% of the embryonic cells, elongate one single neuronal 
process and express GFP under the control of the mec-4 promoter. Treatment 
with 2-DG does not change wild type touch neurons ratio in the cell population or 
their morphology (Fig. 8 A, B and G). As previously published, we found that mec-
4(d) touch neurons undergo degeneration in cell culture. The rarely surviving mec-
4(d) touch neurons do not have neuronal processes or have short processes (Fig. 
8 C and G). Importantly addition of 2-DG to mec-4(d) touch neurons does not 
rescue them from degeneration (Fig. 8 G). These data support the results from 
Calixto and colleagues showing that diapause and caloric restriction rescue mec-
4(d) touch neurons from degeneration via the insulin/IGF-1-like signaling pathway, 
which is disrupted in culture. 
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Fig 8. Effect of block of glycolysis and knock-out of sir-2.3 on mec-4(d)-induced 
neuronal death in cultured cells. A-F: Fluorescent images of wild type, mec-4(d) and sir-
2.3;mec-4(d) touch neurons expressing Pmec-4::GFP cultured in vitro. Cells were in control 
media (A,C,E) or in media containing 10 mM 2-deoxy-glucose(2-DG)(B,D,F). Scale bar is 10 
µm. G: Quantification of surviving touch neurons in culture for the genetic strains shown in 
the micrographs, in control media and in media containing 10 mM 2-DG.  Data are expressed 
as the means ± SE. Same results were obtained in 5 independently performed experiments. 
N is 2 coverslips for each strain (wild type, mec-4(d) and sir-2.3;mec-4(d)) and for both 
conditions (control and 10 mM 2-DG respectively), with at least 10 fields scored per coverslip. 
H: Quantification of surviving touch neurons in culture for an experiment similar to the one 
shown in panel G for mec-4(d) and sir-2.3;mec-4(d). In this case the culturing conditions were: 
control, 10 mM 2-DG, 2.5 µM Rotenone and 10 mM 2-DG + 2.5 µM Rotenone. N is 2 
coverslips each with at least 10 fields scored per coverslip. P was 0.039 and 0.015 (panel G) 
and 0.019, 0.007, 0.00007 and 0.00006 (panel H) by ANOVA with Bonferroni correction. 
 
Interestingly though and in line with the results of in vivo experiments (Fig. 7 A-D), 
knock-out of sir-2.3 still protects neurons from neuronal death in culture and this 
protective effect is further enhanced by treatment with 2-DG. These results, 
support that the rescue of neuronal death afforded by sir-2.3 knock-out is cell-
autonomous, that it’s mediated by a mechanism that at least in part differs from 
the insulin/IGF-1-like signaling pathway and that enables protection afforded by 
2-DG in culture.   
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To test whether the protective effect of sir-2.3 knock-out and 2-DG could be 
overwritten by block of mitochondrial function, we incubated cells with rotenone, 
which blocks complex I in the mitochondrial respiratory chain. Under these 
conditions, we found that the protective effect of sir-2.3 knock-out and of 2-DG in 
this mutant was completely lost, suggesting the requirement of mitochondrial 
function for protection to be carried out (Fig. 7 H).  
 
3.7 MITOHORMETIC ELEVATION OF ROS AND PROTECTION 
AGAINST NEURONAL DEGENERATION  
In mec-4(d) expressing touch neurons undergoing degeneration Reactive Oxygen 
Species (ROS) are elevated and treatment with antioxidants provides protection. 
Given, the striking similarities between mec-4(d) and azide-induced neuronal 
death, we hypothesized that ROS might be elevated also in animals treated with 
azide. To test this possibility, we stained wild type worms treated with 100 mM 
azide for 2 hours with the fluorescent dye DCF, which detects H2O2. As expected, 
we found that DCF fluorescence indicative of ROS was elevated (Fig. 9 A).  
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Fig. 9: ROS in sir-2.3 knock-out animals. A: Quantification of DCF fluorescence in wild type 
and sir-2.3 mutants grown under standard condition, dietary deprivation (DD) or on plates 
containing 5 mM 2-DG for 48 hours with or without treatment with 100 mM Na-azide for 2 
hours. Data are expressed as mean +/- SE, P was (from left to right) 0.0017, 0.0068, 0.042, 
0.00001, and 0.00001 by ANOVA with Bonferroni correction. N was (from left to right) 22, 55, 
23, 68, 25, 23, 23, 16, 38 and 35. B-E: Representative photographs of wild type and sir-2.3 
mutant animals grown under standard condition (B and C) or in dietary deprivation (DD) for 
48 hours (D and E) and stained with the fluorescent ROS indicator DCF. The dotted lines 
correspond to the animal contour. Scale bar is 50 µm. 
 
Diapause entry was shown to mediate protection by activation of superoxide 
dismutases and catalases via the insulin/IGF-1-like signaling pathway. It has been 
suggested that activation of these enzymes is often mediated by mitohormetic 
increase in ROS levels. Mitohormesis is the phenomenon by which a stressor may 
be deleterious at high doses but beneficial at low doses, by activating protective 
mechanisms. We thus hypothesized that starvation and treatment with 2-DG 
might induce elevation of ROS. To test this hypothesis, we cultured wild type C. 
elegans in the absence of food for 48 hours or on plates containing 2-DG and then 
subjected them to treatment with 100 mM azide for 2 hours. Under these 
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conditions, we found that ROS was 6 times more elevated in starved animals and 
animals treated with 2-DG as compared to animals cultured in the presence of 
food. These data suggest that mitohormesis is indeed operative in these 
conditions leading to protection against neuronal death, which we observe in 
starved animals or animals cultured in the presence of 2-DG treated with azide or 
expressing mec-4(d) (Fig. 2 G and 8 A-D). Interestingly, starvation only without 
treatment with azide, does not induce increase of ROS in wild type animals (Fig. 
9 A). 
 
When we compared levels of ROS in sir-2.3(ok444) mutants we noticed 
similarities and some key differences as compared to wild type. Similar to wild 
type, in sir-2.3 animals ROS becomes elevated after 2 hours of azide treatment to 
a level that is similar to the one found in wild type animals (Fig. 9 A). These data 
suggest that protection afforded by knock-out of sir-2.3 is not mediated by 
mitohormetic elevation of ROS, at least not in the presence of food. However, in 
dietary deprived animals and animals cultured in the presence of 2-DG and treated 
with azide, ROS increases only between 2 and 4 folds. Moreover, in the absence 
of azide, dietary deprivation per se induces ROS elevation in sir-2.3 knock-out 
animals (fig.9 A and E). We interpret these results to suggest that knock-out of 
this sirtuin increases the animals sensitivity to dietary deprivation, which results in 
more robust and rapid protection. 
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4. DISCUSSION 
In this work, we investigated the role of C. elegans mitochondrial sirtuin SIR-2.3, 
homologous to mammalian SIRT4, in two distinct models of neuronal death with 
morphological and molecular features of necrosis akin necrosis that occurs in 
cerebral ischemia. We showed that knock-out of sir-2.3 is protective against 
neuronal death in both models, both under severe and mild toxic insults, and that 
protection is enhanced by dietary deprivation and block of glycolysis. We further 
showed that this mechanism of protection is cell autonomous and does not require 
interaction with other cells or secreted molecules. Protection afforded by sir-2.3 
knock-out is distinct from that afforded by entry into diapause and may share only 
downstream targets. Indeed, we showed that in ischemic conditions dietary 
deprivation induce mitohormetic elevation of ROS both in wild type and sir-2.3 
knock-out animals, however the timing, conditions under which this occurs and 
the extent vary. We conclude that knock-out of mitochondrial sirtuin sir-2.3 results 
in changes of mitochondrial function, that result in more efficient response to toxic 
insults, suggesting a deleterious role of SIRT4 during the ischemic processes that 
must to be further investigated. 
 
4.1 INSIGHTS INTO THE ROLE OF MITOHORMETIC ROS IN 
NEURONAL PROTECTION MEDIATED BY HYPERACTIVE 
CHANNELS IN ISCHEMIA 
Elevation of ROS is a mechanism of cellular toxicity operative in many disease 
states including neurodegenerative conditions and cancer. In mec-4(d)-induced 
neuronal death calcium enters the cell through the hyperactivated MEC-4(d) 
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dysfunction and ROS generation. Calixto and colleagues showed that during 
diapause or under caloric restriction inhibition of the insulin pathway leads to daf-
16-mediated activation of antioxidant mechanisms including SODs and catalases, 
which ultimately lead to protection from neuronal death. However, it was not clear 
whether daf-16 directly mediates the transcription of anti-oxidant genes. We 
showed that ROS becomes markedly elevated under dietary deprivation and 
following treatment with 2-DG early on during the toxic insult in a model of 
chemical ischemia (Fig 9). The increase of ROS under dietary deprivation and in 
2-DG is much higher than in animals cultured ad libitum, yet protection is observed 
under these conditions. We interpret these results to suggest that such marked 
increase of ROS functions as mitohormetic signal to induce activation of anti-
oxidant mechanisms. A mitohormetic effect of ROS has been previously 
suggested to explain the effect of caloric restriction in other models. Interestingly, 
the protective effect of 2-DG is not present in culture (Fig. 8), suggesting that 
under these experimental conditions mitohormetic increase of ROS is not 
occurring or is strongly attenuated and/or downstream activation of anti-oxidant 
mechanisms is absent in culture. We suggest that this is because FBS used in the 
culture media contains insulin like ligands which likely interact with DAF-2 to 
maintain the insulin pathway active which results in suppression of DAF-16 
translocation into the nucleus. 
 
4.2 KNOCK-OUT OF MITOCHONDRIAL SIRTUIN sir-2.3 AND ROS 
Our data suggest that when sir-2.3 is knocked-out, an additional mechanism of 
protection is activated. SIR-2.3 shares the highest homology with mammalian 
SIRT4 (42% identity and 62% similarity). Like SIRT4, SIR-2.3 is expressed in 
neurons and is localized in mitochondria [136]. The enzymatic activity of SIRT4 
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has been a subject of debate because a SIRT4-mediated deacetylase activity 
could not be initially identified. However, recently SIRT4 has been reported to 
have specific deacetylase activity toward malonyl CoA decarboxylase. Similarly, 
sir-2.3 mediated deacetylase activity has not been demonstrated, however, sir-
2.3 interacts with several highly acetylated mitochondrial carboxylases including 
mitochondrial biotin-dependent carboxylases, pyruvate carboxylase, propionyl-
CoA carboxylase and methylcrotonyl-CoA carboxylase, suggesting that indeed 
sir-2.3 controls their level of acetylation. SIRT4 possesses also ADP-ribosylase 
activity and one of its targets is the mitochondrial enzyme glutamate 
dehydrogenase (GDH) [136], which mediates the conversion of glutamate into 
alpha-keto glutarate, a Krebs cycle intermediate. By mediating ADP-ribosylation 
of GDH, SIRT4 inhibits the activity of this enzyme resulting in repression of 
glutamine metabolism. Knock-out of SIRT4 is expected to induce increase of the 
concentration of alpha-ketoglutarate due to disinhibition of GDH. Interestingly, 
alpha-ketoglutarate is a ROS scavenger. Thus, knock-out of SIRT4 may 
predispose the cell to increased resistance to oxidative stress especially when 
paired with block of glycolysis, which forces the cell to use amino acid metabolism 
for energy production. Moreover, compared to other sirtuins, SIRT4 has a peculiar 
expression in brain and is involved in controlling serotoninergic pathway, which is 
pivotal in regulating oxidative stress, and insulin/IGF-1 signaling pathway in 
neurons [137]. 
 
We do not know whether SIR-2.3 has ADP-ribosylase activity, however, it is 
interesting to note that a transgenic strain carrying a GFP tagged sir-2.3 transgene 
shows severe loss of resistance to oxidative stress (paraquat). Our data do not 
show more extensive neuronal death in transgenic worms overexpressing sir-2.3 
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(Fig 2), but they show that ROS production is strongly attenuated in sir-2.3 knock-
out animals under conditions of chemical ischemia, when paired with dietary 
deprivation or block of glycolysis (2-DG) (Fig. 9). An implication of the amino-acid 
metabolism and of ROS scavenger alpha-ketoglutarate in the protection against 
neuronal death mediated by knock-out of sir-2.3 is further supported by our results 
in cell culture. Here, the effect of 2-DG on neuronal survival is even more robust 
than in vivo (compare Fig. 7 with Fig. 8). We suggest that this is due to the culturing 
conditions. Indeed, the culture media used for the treatment with 2-DG contains 
glutamine, which is expected to further increase the activity of GDH in the absence 
of sir-2.3. Interestingly, sir-2.3 knock-out animals show elevated ROS under 
dietary deprivation in the absence of toxic insult (Fig. 8). This result is again 
consistent with elevated levels of alpha-ketoglutarate in sir-2.3 knock-out strain 
under conditions that force the cell to switch to amino-acid metabolism, which 
stimulates the Krebs cycle and therefore induce elevation of ROS via both the 
Krebs cycle and the respiratory chain. As a further support that mitohormetic 
production of ROS mediates the protective effects of knock-out of sir-2.3 and 
caloric restriction, block of the complex I of the respiratory chain by rotenone, 
completely eliminates protection (Fig. 8). Indeed, under these conditions, it is 
expected that the majority of ROS production is eliminated. In line with our 
observations, it has been recently shown that direct activation of GDH by 
activators protects against brain ischemia and reperfusion.  
 
Importantly, our data show that protection afforded by block of glycolysis has 
distinct effects depending on whether sir-2.3 is present or not in the cell. When 
sir-2.3 is present the effect is mainly mediated by the insulin pathway, as Calixto 
and colleagues have shown. When sir-2.3 is knocked-out, the effect does not 
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require interaction with other cells or secreted molecules. We interpret this result 
as supportive evidence that 2-DG or dietary restriction/deprivation force the cell to 
switch to amino acid metabolism and therefore production of ROS scavenger 
alpha-ketoglutarate and this is how protection is mediated under these conditions.  
Interestingly, when the sir-2.3 knock-out animals are cultured at libitum and are 
subjected to chemical ischemia, they show an increase in ROS early on during 
treatment that is identical to the increase in ROS observed in wild type animals 
(Fig. 8, first 4 bars). This result suggests that the protection mediated by knock-
out of sir-2.3 per se is independent of ROS and may be related to sir-2.3 
deacetylase activity.  
 
We have shown here that the knock-out of mitochondrial sirtuin protects neurons 
from ischemic damage, especially when paired with dietary deprivation or block of 
glycolysis, which forces the cell to switch to amino acid catabolism through 
activation of glutamate dehydrogenase. Furthermore, we showed that protection 
appears to be mediated by mitohormetic elevation of ROS. Our work extends our 
understanding of mitochondrial situins and of the interplay of glycolysis, Krebs 
cycle and respiratory chain in the control of the cellular redox state and survival. 
Given, the parallelism between the models of neuronal death used in this work 
and ischemia in humans, our work suggests novel approaches targeting SIRT4 
and cautions about the use of non-specific sirtuins activators or inhibitors. 
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